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ABSTRACT 
 
JENNIFER L. LUND: The validity of administrative data and patterns of 
chemotherapy use among elderly colorectal cancer patients  
(Under the direction of Dr. Til Stürmer) 
 
Chemotherapy represents an integral part of the treatment plan for many 
cancer patients, proven to decrease recurrence and overall mortality. Recent 
trials demonstrated that adding oxaliplatin to 5-fluorouracil/leucovorin significantly 
improved survival for stage III colon cancer patients. However, few studies have 
examined the translation of these findings into routine practice, particularly 
among the elderly, who are underrepresented in trials.    
Two population-based data sources were linked to assess the utility of 
Medicare claims in identifying chemotherapy and specific agents administered to 
elderly stage II/III colorectal cancer (CRC), in-situ/early stage breast, non-small 
cell lung, and ovarian cancer patients. The National Cancer Institute’s Patterns of 
Care (POC) studies collected data on chemotherapy by reviewing hospital and 
medical records and contacting physicians. POC data were linked and compared 
to Medicare claims and measures of agreement and validity were estimated.  
Using validated definitions, we constructed a cohort of stage II/III CRC 
patients from the Surveillance, Epidemiology, and End Results program (SEER)-
Medicare linked database to 1) estimate trends in the utilization of agents over 
time and 2) identify patient, physician, and hospital characteristics associated 
 iv
with the receipt of oxaliplatin using Poisson regression models and a generalized 
estimating equation (GEE) strategy for non-nested clustering.     
Overall, the sensitivity and specificity of Medicare claims to identify any 
chemotherapy were high; however, we found variation across agents, sites and 
administration modalities. Shifts in utilization of specific agents were seen from 
2000–2007, with increasing oxaliplatin and capecitabine use. Younger age, being 
married, fewer comorbidities, low-poverty areas, colon cancer diagnosis, and 
stage III disease were associated with oxaliplatin use.  
Validated Medicare definitions identified a substantial increase in 
oxaliplatin utilization from 2004-2007 for both on- and off-label indications. 
Patient characteristics were most influential in explaining the variation in 
oxaliplatin receipt. Off-label use of chemotherapeutic agents was relatively 
common. Physicians should carefully weigh the minimal (if any) or unknown 
benefits of treatment against potentially serious side effects when deciding 
whether to treat a patient off-label.
 v
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CHAPTER 1 
 
STATEMENT OF SPECIFIC AIMS 
 
Colorectal cancer (CRC) is the third leading cause of cancer death in men 
and women in the United States (US) and accounts for approximately 142,000 new 
cases each year. The incidence of CRC increases steadily with age, with men 
generally having a higher incidence rate than women.1 However, when the number 
of cases by age and sex are estimated, older women tend to take on a large portion 
of the overall burden, as they generally have longer life expectancies. CRC is a 
disease primarily of the elderly with a median age at diagnosis of 72 years old, 
representing a significant disease burden among elderly individuals in the US.  
Chemotherapy plays an important role in the treatment plan of cancer, as it 
has been shown to decrease the risk of recurrence and overall mortality. Recent 
clinical trials have documented the efficacy of new chemotherapeutic agents for the 
treatment of CRC. In particular, a recent trial demonstrated that adding oxaliplatin to 
fluorouracil plus leucovorin (5-FU) significantly improved 5-year disease-free and 6-
year overall survival for individuals diagnosed with stage III, but not stage II colon 
cancer. In November 2004, the Food and Drug Administration approved oxaliplatin 
for the treatment of stage III colon cancer.  
Medicare claims are frequently used to track trends and evaluate 
chemotherapy use in the elderly because of their longitudinal and population-based 
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features. Prior studies have shown that Medicare claims can be reliably used to 
identify overall chemotherapy use; however, their ability to identify a variety of 
specific agents, including oxaliplatin, remains unknown. Furthermore, few studies 
have examined the translation of trial evidence on oxaliplatin into routine practice, 
particularly among individuals diagnosed with stage II colon or stage II or III rectal 
cancers (off-label indications) and the elderly, who are often excluded from trials.  
This dissertation addressed the following questions: 
1) Can Medicare claims be used to accurately capture the receipt of any 
chemotherapy and specific chemotherapeutic agents as part of the initial 
course of treatment among individuals diagnosed with early stage breast 
cancer, stage II and III CRC, non-small cell lung cancer, and ovarian cancer? 
2a) What is the prevalence of specific chemotherapeutic agent utilization from 
2000-2007 among stage II and III CRC?  
2b) What are the independent patient, physician, and hospital characteristics 
that influence the receipt of oxaliplatin?  
To answer these questions, the following specific aims were addressed in this 
research: 
 
Specific Aim 1  
Assess the utility of Medicare claims to capture the receipt of any chemotherapy 
and specific agents delivered to patients diagnosed at age ≥65 with stage II or III 
colorectal cancer (CRC), in situ or early stage breast, non-small cell lung cancer 
(NSCLC), or ovarian cancer using various post-diagnosis claims windows. 
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Hypothesis - Specific Aim 1  
The Se and Sp of Medicare claims to identify the receipt of any chemotherapy 
will be high (>85%) for all cancer sites. A longer post-diagnosis window will improve 
the Se for identifying the receipt of specific chemotherapeutic agents in Medicare 
data. The Se and Sp of specific agents will vary by agent, cancer site, mode of 
administration, and post-diagnosis period.    
 
Rationale for Specific Aim 1  
Prior studies have confirmed that Medicare claims can be used to identify the 
receipt of any chemotherapy. However, the validity of using Medicare claims to 
identify the use of newly approved agents such as oxaliplatin and capecitabine have 
not been evaluated. In addition, there is a lack of guidance on how long of a post-
diagnosis window is appropriate for the assessment of the initial course of 
chemotherapy. An updated assessment of prior studies may provide insight into 
improvements in coding of specific agents over time.  
  
Specific Aim 2a 
Estimate the prevalence of specific chemotherapeutic agent utilization (5-FU, 
capecitabine, oxaliplatin, irinotecan, and bevacizumab) from 2000-2007 among 
elderly stage II and III CRC patients. Stratify the prevalence analysis by cancer site 
and stage to examine on- and off-label utilization.   
 
Hypothesis - Specific Aim 2a  
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The prevalence of 5-FU will decrease over the period from 2000-2007 for all 
cancer site and stage groups, while the prevalence of capecitabine and oxaliplatin 
will be highest among stage III colon cancer patients (i.e., on-label indication). The 
utilization of irinotecan will decrease over the time period. Bevacizumab utilization 
will be low over the entire time period for all cancer site and stage groups.  
 
Rationale for Specific Aim 2a 
Prior studies have focused mainly on examining trends in the receipt of any 
chemotherapy or guideline concordant treatment. The few studies that have 
examined trends in specific chemotherapeutic utilization have mainly focused on 
patients diagnosed with stage III colon or metastatic CRC. Little is known about the 
utilization of specific chemotherapeutic agents among stage II colon and stage II and 
III rectal cancer patients. Updated information will provide a more timely 
representation of current patterns of chemotherapy use. 
 
Specific Aim 2b 
Identify independent patient, physician, and hospital characteristics associated 
with the receipt of oxaliplatin among elderly stage II and III CRC patients who 
receive chemotherapy. Stratify analyses by on- and off-label indication.    
 
Hypothesis - Specific Aim 2b  
Younger patients and those with little comorbidity will be more likely to receive 
oxaliplatin. By conditioning on the receipt of chemotherapy, race/ethnicity and other 
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area level measures of socioeconomic status (SES) will not be associated with the 
receipt of oxaliplatin. Physicians who more recently graduated from medical school 
will be more likely to provide oxaliplatin to their patients. Patients undergoing surgery 
at larger hospitals, those with an NCI clinical or comprehensive cancer center 
designation, and those with NCI cooperative group participation will be more likely to 
receive oxaliplatin.      
 
Rationale for Specific Aim 2b 
Prior studies have shown that a number of patient and tumor characteristics are 
strongly associated with the receipt of any chemotherapy. However, few studies 
have examined patient, physician, and hospital factors related to receipt of 
oxaliplatin among those who receive some chemotherapy. Of the studies that have 
been conducted, stage II colon and stage II and III rectal cancer patients are often 
excluded from analysis. Off-label use of oxaliplatin is common, but it is unknown 
whether the factors that predict on- and off-label use are the same. 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER 2 
 
REVIEW OF LITERATURE 
A. BACKGROUND 
Public health significance of colorectal cancer 
Colorectal cancer (CRC) places a significant burden on the United States (US) 
health care system as the third leading cause of cancer death among men and 
women. In 2010, there were an estimated 142,570 newly diagnosed cases and 
51,370 deaths attributable to CRC, leading to approximately $8.9 billion in health 
care spending.2,3 The median age at diagnosis for CRC is 71 years old; therefore, as 
the overall US population ages, the burden of incident and likely prevalent CRC will 
continue to increase.4-6  
The TNM system is one of the most commonly used cancer staging systems 
and was developed by the American Joint Commission on Cancer (AJCC) and the 
International Union Against Cancer (UICC). The TNM staging system requires three 
pieces of information to stage a cancer: 1) the tumor size and number of tumors (T); 
2) lymph node involvement (N); and 3) the presence or absence of metastasis (M). 
The prognosis for a patient depends greatly on the stage of cancer at diagnosis. For 
example, the 5-year overall survival for stage I CRC is higher than 90% while the 
overall survival declines to less than 10% for stage IV CRC.7    
Based upon data from the Surveillance, Epidemiology and End Results Program 
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(SEER), approximately 50% of all CRCs are diagnosed at stage II or III, representing 
a large proportion of the total CRC burden.8 Five-year relative survival rates for 
stage II and III CRC are 70% and 56%, respectively, indicating the need for 
additional treatments or wider dissemination and access to effective treatments that 
extend survival and improve quality of life.9 
 
Role of chemotherapy in the treatment of stage II and III colorectal cancer 
 Guidelines for the treatment of stage II and III CRC have changed over time, 
but have generally included a combination of surgery, radiation, and/or 
chemotherapy.10,11 For many individuals, chemotherapy (either neoadjuvant and/or 
adjuvant) represents an integral part of the treatment plan, proven to decrease the 
risk of disease recurrence and overall mortality.12-19  
 
Randomized controlled trial evidence: stage II and III colon cancer 
 The mainstay of chemotherapeutic treatment since the late 1990’s for colon 
cancer has been 5-fluorouracil (5-FU). 5-FU is a fluoropyrimidine that acts primarily 
through inhibiting thymidylate synthetase, the rate-limiting enzyme in pyrimidine 
nucleotide synthesis.20 When 5-FU was combined with another vitamin, leucovorin, 
efficacy of the treatment was found to be greatly enhanced.21  
 Capecitabine is an oral chemotherapeutic prodrug, meaning that through a 
series of enzymatic steps, it preferentially forms 5-FU in tumor tissue.22 Capecitabine 
was tested in an equivalency trial, the Xeloda in Adjuvant Colon Cancer Therapy (X-
ACT) trial, which compared intravenous bolus 5-FU/LV (Mayo Clinic regimen) with 
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oral capecitabine for 6 months in stage III colon cancer. The study found that across 
study arms, there were no differences in disease free survival (DFS) or levels of 
toxicity.19 
 A number of fluoropyrimidine combinations were subsequently investigated in 
metastatic CRC (mCRC) patients starting the mid-1990’s. These trials found that 
that the addition of oxaliplatin or irinotecan to 5-FU/LV substantially improved 
progression free survival (PFS) and overall survival (OS). To determine whether the 
improved efficacy observed in the metastatic setting translated into benefits in earlier 
stage disease, four trials were conducted among stage II and III colon cancer 
patients. 
Three phase III RCTs were conducted examining the addition of oxaliplatin to 
various fluoropyrimidine regimens. The first was the Multicenter International Study 
of Oxaliplatin/5-FU/LV in the Adjuvant Treatment of Colon Cancer (MOSAIC) trial, 
which included 2246 patients with stage II and stage III colon cancer and compared 
a 5-FU/LV regimen against an oxaliplatin-enhanced regimen (FOLFOX4) for 6 
months. After 6 years of follow-up, FOLFOX4 extended DFS (HR=0.80; p=0.003) 
and OS (HR=0.84, p=0.046) for individuals diagnosed with stage II and III colon 
cancer compared to the 5-FU/LV regimen alone. However, when the follow-up trial 
results were stratified by stage, the increased effect of oxaliplatin on OS and DFS 
was driven primarily by stage III patients and no difference in OS was seen in the 
stage II group.13 The second trial was the National Surgical Adjuvant Breast and 
Bowel Project (NSABP) trial C-07, which evaluated the FLOX regimen (oxaliplatin 
added to weekly bolus of 5-FU/LV) in 2,492 patients with stage II and stage III colon 
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cancer. The DFS findings from this trial were consistent with those demonstrated in 
the MOSAIC study (HR=0.80, p=0.004).23 The final combination trial was the 
NO16968 which examined whether capecitabine plus oxaliplatin (XELOX) was 
superior to bolus 5-FU/LV. Consistent with the prior two studies, adjuvant therapy 
with XELOX significantly improved DFS in stage III colon cancer in the (HR=0.80, 
p=0.0045).24    
Two similar trials examining the addition of irinotecan to a 5-FU regimen were 
conducted among stage II and III colon cancer patients, based on the success of the 
combination treatment in the metastatic setting. However, all three trials failed to 
show any DFS or OS benefit for the combination.25,26 A summary of these trials is 
provided in Table 2.1 below.  
  
Randomized controlled trial evidence: stage II and III rectal cancer 
Because of the location of rectal cancer and an increased risk of local recurrence 
and a poorer overall prognosis, its treatment is somewhat different than colon 
cancer. Specifically, rectal cancer management often requires radiation and different 
surgical techniques. Regarding chemotherapy treatment, in the late 1980’s, 
postoperative chemotherapy was considered the standard of care as demonstrated 
in the NCCTG-864751 trial showing that the administration of 5-FU during pelvic 
irradiation improved the effect of combined-treatment postoperative adjuvant therapy 
in stage II and III rectal cancer patients.27 A subsequent trial conducted in North 
America demonstrated that the addition of leucovorin to fluorouracil during radiation 
did not improve disease-free or overall survival.28 Finally, in 2004, the German 
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Rectal Cancer Study Group randomized trial compared preoperative and 
postoperative chemoradiotherapy in 823 patients with stage II or III rectal cancer. 
Study results showed that preoperative chemoradiation therapy increased the rate of 
sphincter-sparing operations and lowered the overall rates of local recurrence and 
toxicities. Based on this data, preoperative chemoradiotherapy has become the 
standard of care in stage II and III rectal cancer.29 A summary of these trials is 
provided in Table 2.2 below. Currently, RCT evidence from colon cancer is used to 
support pre- and post-operative treatment with oxaliplatin in rectal cancer patients. 
However, one RCT is underway examining the efficacy of preoperative 
chemoradiotherapy, surgery, and postoperative chemotherapy comparing 
chemotherapy regimens of capecitabine or 5-FU in combination with or without 
oxaliplatin among stage II and III rectal cancer patients. Preliminary findings show 
that the addition of oxaliplatin to preoperative 5-FU or capecitabine treatment did not 
improve preliminary outcomes, but resulted in substantial toxicity.30    
 
Food and Drug Administration approval and off-label use of chemotherapy 
drugs 
 Food and Drug Administration (FDA) approval for all new drugs is based 
largely on the results of pivotal phase III trials. However, there are specific 
mechanisms in place such as fast track, accelerated approval, and priority review 
which seek to expedite the approval process and minimize the time from application 
to marketing of the drug.  Often times, cancer drugs will receive fast track or priority 
status because they tend to address “serious diseases with unmet medical needs” or 
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they offer “major advances in treatment or provide a treatment where no adequate 
therapy exists.”31  
However, when a drug is used for a purpose other than its approved FDA 
indication, it is considered an off-label use. Prescribing for off-label indications is 
common in oncology primarily due to a lack of effective treatments and the relatively 
low survival rates associated with late stage disease. In fact, according to the 
National Comprehensive Cancer Network (NCCN), between 50 – 75% of all cancer 
therapies in 2005 were used off-label.32,33 Capecitabine and oxaliplatin are currently 
approved by the FDA for use in treatment of patients with metastatic CRC and for 
patients with stage III colon cancer.34 However, little is known about the magnitude 
or distribution of its off-label use in individuals diagnosed with stage II colon or stage 
II or III rectal cancer.  
 
Clinical guidelines and recommendations 
Guidelines and recommendations for the treatment of CRC have changed 
substantially over time, primarily due to innovations in treatments. The NCCN 
guidelines are the recognized standard for clinical policy in oncology. The guidelines 
are updated on a continual basis and are developed through an explicit review of the 
evidence integrated with expert medical judgment by multidisciplinary panels.10,11  
For individuals diagnosed with stage III colon cancer, the NCCN recommends 
6 months of adjuvant chemotherapy treatment with FOLFOX, and oxaliplatin-
containing regimen, as it has been shown to be superior to 5-FU/LV alone.10 
However, among patients that may be inappropriate to treat with FOLFOX (e.g., 
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those with particular comorbidities), a regimen of 5-FU/LV may be recommended.35-
37
  
Among individuals diagnosed with stage II colon cancer of high to 
intermediate risk of recurrence (as defined above as “high-risk”), NCCN believes that 
treatment with FOLFOX is reasonable.38 Adjuvant therapy among low-risk stage II 
colon cancer patients remains controversial and the NCCN has recommended 
against its routine use in low-risk stage II patients.39 However, a recent non-
experimental study published by O’Connor et al found that adjuvant chemotherapy 
did not result in improved overall survival for stage II colon cancer patients with or 
without high risk features.40 
Current NCCN recommendations for the treatment of stage II and III rectal 
cancer include initial surgery with chemoradiation therapy, although some 
controversy remains as to whether pre- or postoperative chemoradiation therapy is 
more beneficial.11 For those individuals who receive preoperative 
chemoradiotherapy, postoperative treatment with oxaliplatin is recommended, yet 
specific sub-groups of individuals diagnosed with stage II rectal who may benefit are 
still unclear.41-43 The current support for the use of oxaliplatin in rectal cancer is 
derived primarily from clinical trials in colon cancer.  
 
B. IDENTIFICATION OF CHEMOTHERAPY IN ADMINISTRATIVE DATA 
The role of administrative data sources in pharmacoepidemiology  
 Over the last 25 years, there has been increased interest in using automated 
healthcare claims databases for research. These data are prospectively collected for 
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administrative or billing purposes, but often contain detailed longitudinal information 
on demographic characteristics and healthcare utilization for a large number of 
covered individuals under discrete health insurance plans. These data are not 
subject to biases that may arise in primary data collection such as recall and 
interviewer bias because there is no direct interaction with the patients. Furthermore, 
some automated databases may be population-based, which aids in the 
generalizability of the findings to a defined group of individuals. Lastly, these data 
are particularly appealing because they tend to be cost-effective (relative to the 
costs of collecting primary data) and efficient (regarding the amount of time it may 
take to complete an analysis).44 However, these data are often lacking important 
clinical information that may be required to conduct an unbiased study. As such, 
linkages between disease registries or electronic health records and administrative 
claims data can greatly improve the quality of the database for research purposes. 
 
Uses of the Surveillance, Epidemiology, and End Results program (SEER)-
Medicare linked database 
One such example is the Surveillance, Epidemiology, and End Results 
program (SEER)–Medicare linked database. The SEER-Medicare consists of a 
linkage of two large population-based data sources providing detailed clinical and 
healthcare utilization information on Medicare beneficiaries diagnosed with cancer.4 
The SEER 17 registries collect demographic, clinical and tumor characteristics, vital 
status, and cause of death for all incident cancers reported for individuals who reside 
in one of the registries’ defined geographic areas, currently covering approximately 
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28% of the US population.45 These data have been linked to Medicare enrollment 
and Part A (Hospital insurance) and B (Medical insurance) claims data. 
Approximately 93% of all elderly cancer patients in SEER have been matched to 
Medicare enrollment files with an established algorithm, resulting in a linked 
database that includes over 3.3 million elderly individuals (age ≥ 65 years).46 Nearly 
all Medicare beneficiaries are eligible for Part A and close to 93% opt to enroll in the 
Part B.47    
 
Utility of SEER-Medicare data to identify chemotherapy use 
The SEER-Medicare data can be used to examine a wide range of research 
topics across the trajectory of care for elderly cancer patients. In particular, the data 
are increasingly used to conduct non-experimental studies evaluating the uses, 
benefits, and harms of chemotherapeutic treatments among individuals excluded 
from trials, including older adults, those with multiple co-morbidities, and those 
treated off-label. 
 The validity of these studies relies upon a variety of issues, including the 
ability of claims data to accurately capture treatment(s) of interest, study endpoint(s), 
and other important design and clinical issues.48 Measurement error in the 
assessment of chemotherapy could lead to biased study results. Prior studies have 
examined the validity of Medicare claims data to identify chemotherapy. A study by 
Warren et al49 assessed the utility of Medicare claims data for identifying the receipt 
of chemotherapy among individuals diagnosed with in situ or early stage breast, 
stage II or III CRC, and ovarian cancer. The authors calculated the sensitivity of 
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Medicare claims dies to identify the receipt of chemotherapy compared to 
information obtained from the Patterns of Care (POC) studies in 1991 and 1995. The 
POC studies collected the gold standard treatment information through re-
abstraction of hospital data, physician confirmation of outpatient treatment, and 
review of medical records. They authors found that for all cancer sites, the Se of 
identifying any chemotherapy use was high (>88%); yet, the Se and Sp of specific 
agents varied.49  
 Another study examined the validity of Medicare inpatient and outpatient 
claims for identifying specific agents in comparison to two Cancer and Leukemia 
Group B (CALGB) trials among breast (1995-1997) and lung (1998-2000) cancer 
patients. The study reported the Se and Sp for doxorubicin were 91% (95% CI: 79%, 
98%) and 100%, respectively and for paclitaxel were 86% (79%, 92%) and 100%, 
respectively.50 
 
Rationale for Aim 1: 
Prior research studies support the validity of Medicare claims data to identify 
intravenously administered chemotherapy treatment for a variety of cancer sites,49-53 
but do not address more recently approved or orally administered agents or changes 
in validity using multiple claims windows following diagnosis.  
Therefore, the first aim of this dissertation was to assess the utility of 
Medicare claims for capturing the receipt of any chemotherapy and specific agents 
delivered to patients diagnosed at age ≥65 with stage II or III colorectal cancer 
(CRC), in situ or early stage breast, non-small cell lung cancer (NSCLC), or ovarian 
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cancer. This assessment 1) evaluated the validity of selected single agent 
chemotherapies, including an orally-administered agent and 2) described the 
variation in measures of validity for any chemotherapy and specific treatments over 
multiple follow-up periods and across cancer sites. This updated validation study will 
provide contemporaneous information for researchers to use to assess the impact of 
treatment misclassification in their studies and conduct sensitivity analyses 
attempting to correct for this bias.   
 
C. UTILIZATION OF CHEMOTHERAPY TREATMENT AMONG STAGE II AND III 
COLORECTAL CANCER PATIENTS 
Generalizability of RCT evidence of chemotherapy treatment among colorectal 
cancer patients 
 RCTs examining the efficacy of chemotherapeutic treatments are conducted 
within relatively small, well-defined populations in order to isolate the effect of the 
treatment on DFS and OS. However, this selection reduces the generalizability of 
the study results to the general cancer population, which tends to be older and less 
healthy. The median age of patients enrolled in the two primary oxaliplatin trials, 
MOSAIC and NSABP C-07 were 61 and 59 years,23,41 respectively; however, the 
median age of diagnosis for stage II and III CRC is 71 years. Additionally, trial 
participants were also relatively healthy, with over 90% having an Eastern 
Cooperative Oncology Group performance score of < 2,54 indicating good overall 
health and physical activity. The discrepancy between the selected trial populations 
and the general CRC cancer population can lead to uncertainty in translation of the 
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RCT evidence into routine practice, particularly among the elderly and patients with 
more comorbidity.   
  
Observational studies of chemotherapy utilization in stage II and III colorectal 
cancer 
 The overall use of drug therapies in community clinical practice is a 
combination of approved and off-label use. Tracking treatment utilization is important 
for assessing the dissemination of RCT evidence and clinical guidelines into routine 
clinical practice, particularly among populations who are excluded from trials, such 
as the elderly. Many studies have examined trends in the utilization of chemotherapy 
treatment or guideline concordant treatment over time; however few have focused 
specifically on stage II and III CRC patients. However, the National Cancer Institute 
(NCI) initiated the POC studies in response to a congressional mandate to report on 
the dissemination of state-of-the-art therapy into community practice. The POC 
studies utilize information from the SEER cancer registries and thus are population-
based. The first study by Potosky et al55 reported trends in adjuvant 5-FU utilization 
among a cohort of stage II and III colon cancer patients and adjuvant chemotherapy 
and radiotherapy utilization among stage II and III rectal cancer patients of all ages 
diagnosed from 1987-1995. The study found that stage III colon cancer patients had 
higher utilization of adjuvant 5-FU when compared to stage II colon cancer patients, 
which was consistent with clinical guidelines. Uptake of 5-FU was most notable 
between 1989 and 1990 for this group. Among the stage II and III rectal cancer 
patients, combined adjuvant chemotherapy with radiation increased starting around 
  18 
1989, which marked the decline in the utilization of radiation therapy alone. Similar 
to colon cancer, the utilization of chemotherapy and radiotherapy were higher 
among stage III compared to stage II rectal cancer patients, reflecting the lower risk 
of recurrence in earlier stage cancer. For both colon and rectal cancers, utilization of 
chemotherapy was much lower for patients diagnosed at age ≥ 75 years over the 
entire time period, potentially signaling an issue with “ageism.”55 Pooled analyses 
have repeatedly found that elderly individuals derive similar benefit from adjuvant 
chemotherapy treatment with no increased toxicity.56   
 An update to the first POC study was published by Cronin et al and examined 
the dissemination of guideline concordant treatment for stage III colon and II and III 
rectal cancer patients of all ages diagnosed from 1987-1991, 1995, and 2000. 
Guideline concordant therapy was defined as adjuvant 5-FU treatment for stage III 
colon cancer and adjuvant 5-FU and radiotherapy for rectal cancer. Over the time 
period, guideline concordant therapy increased among stage III colon and stage II 
rectal cancer patients, but slightly decreased for stage III rectal cancer patients. 
Similar to the findings by Potosky et al, older individuals (≥ 75 years) were 
substantially less likely to receive guideline concordant therapy across all cancer site 
and stage groups in 1995 and 2000. 
  Ferro et al57 published a cross-sectional study based on treatment 
information from 115 ambulatory centers in the US to examine the utilization of 8 of 
the most commonly prescribed chemotherapeutic regimens by 421 individuals 
diagnosed with CRC between 2002 and 2005. Almost 50% of the individuals in this 
cohort were diagnosed with mCRC. The most common regimens were 5-FU/LV 
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(35%), irinotecan-containing (26%), and oxaliplatin-containing (25%) treatments. 
This pattern was generally consistent across regions, however, use of oxaliplatin 
varied somewhat by region (29.7% in the South vs. 2.5% in the West), which may 
reflect patterns in HMO penetration. As expected, the percentage utilization of 
oxaliplatin substantially increased from 0% in March 2002 to 61% by 2005.   
 The SEER-Medicare data have also been used to track the utilization of 
chemotherapy treatment for CRC. A recent cohort study by Hsiao et al58 sought to 
compare the effectiveness and utilization of 5-FU/LV, irinotecan-based and 
oxaliplatin-based chemotherapeutic regimens for elderly (≥ 66 years) stage III colon 
cancer patients diagnosed from 2002-2005. The study identified 4,614 stage III 
colon cancer patients who received chemotherapy after colon resection. Over the 
time period, 5-FU/LV utilization decreased from 32% in 2002 to 15% in 2005, 
irinotecan-based regimens decreased from 37% in 2000 to 14% in 2005, and 
oxaliplatin-based regimens increased from 35% in 2004 to 57% in 2005. A similar 
pattern of age effects on utilization was seen, where the initial uptake and 
prevalence of treatment with newer agents (i.e., irinotecan and oxaliplatin) was low 
among patients diagnosed at older ages.     
 The most recent study published on the utilization of specific chemotherapies 
for stage II and III colon cancer was conducted by Abrams et al 59 and used data 
from an outpatient chemotherapy ordering system in the US. This cross-sectional 
study identified patients receiving adjuvant chemotherapy between 2004 and the 
beginning of 2010. In 2004, 39% of stage III colon cancer patients received 
oxaliplatin with a fluoropyrimidine, but by 2007, this percentage increased to 90%. 
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Stage II colon cancer patients also experienced a rapid increase in oxaliplatin 
receipt, reaching 79% by 2008. Older age was again associated with decreased 
receipt of oxaliplatin in both stage II and III colon cancer patients. Table 2.3 
summarizes the study characteristics and results from the relevant literature on 
chemotherapy utilization among stage II and III CRC patients.        
 
Rationale for Aim 2a: 
 Considering the breadth of literature in this area, questions remained about the 
utilization of a specific chemotherapeutic agents among stage II and III CRC 
patients. The majority of studies report utilization data through the end of 2005, with 
the exception of Abrams et al. Therefore, more timely data on the prevalence of 
treatment with specific chemotherapeutic agents for elderly stage II and III CRC 
patients and trends over a longer period of time are indicated. In addition, many 
specific chemotherapeutic agents of interest are only approved for stage III colon 
and stage IV CRC, but are being used off-label in stage II colon and stage II and III 
rectal cancer. The benefits of treatment in these groups are unknown or possibly 
minimal, yet known side effects associated with these treatments exist. Therefore, it 
is important to understand patterns in utilization of specific agents among off-label 
groups, particularly in stage II and III rectal cancer where limited data exist. 
Capecitabine is an oral prodrug that has been shown to have equivalent efficacy to 
5-FU/LV, but with less toxicity. However, data on trends in the replacement of 5-FU 
with capecitabine are lacking.  
This dissertation addressed the above questions using a more 
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contemporaneous data source (the SEER-Medicare linked database containing 
health care utilization data through 2008) and stratified analyses by cancer site and 
stage in order to report trends in off-label use.  
 
D. OBSERVATIONAL STUDIES ON THE INFLUENCE OF PATIENT, PHYSICIAN, 
AND HOSPITAL CHARACTERISTICS ASSOCIATED WITH THE RECEIPT OF 
OXALIPLATIN IN STAGE II AND III CRC 
 A vast literature has developed around examining patterns of health services 
use among cancer patients. For simplicity, the literature can be divided into three 
phases on the continuum of care: 1) diagnosis and initial treatment, including 
surgery, chemotherapy, radiotherapy, 2) post-diagnostic surveillance and 
survivorship, and 3) terminal or end-of-life care.46 To evaluate patterns of care 
among cancer patients, a conceptual model such as the Andersen Behavioral 
Model,60 adapted and pictured below in Figure 2.1, are often used to provide a 
framework for developing research studies.  
 The focus of this review is to summarize the literature that specifically 
examines patterns of oxaliplatin treatment among stage II and III CRC. However, a 
great deal of work has already focused more broadly on patient, physician, and 
facility characteristics associated with the receipt of any chemotherapy among CRC 
patients. I will first briefly summarize the broad chemotherapy literature and then 
focus specifically on the literature relevant to oxaliplatin. 
 
Patient, physician and hospital characteristics and the receipt of chemotherapy 
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among stage II and III CRC           
 As shown in the conceptual model above, patient characteristics such as age, 
sex, race/ethnicity, marital status, comorbid conditions, and income can all be 
classified as predisposing factors that may be related to the receipt of health 
services. A number of studies have examined patient factors that are associated 
with chemotherapy treatment in stage II and III CRC. One area of research has 
focused on racial disparities and the receipt of chemotherapy. Findings have 
consistently shown that Black Non-Hispanics diagnosed with stage II or III CRC are 
substantially less likely to receive chemotherapy than White Non-Hispanics, even 
after controlling for consultation with a medical oncologist.55,61-69 Access to care, 
patient preferences, and patient-provider interactions have all been hypothesized as 
potential areas for further research to investigate reasons for this disparity.  
 Another area of intense research has investigated the effect of age at diagnosis 
and the receipt of chemotherapy. In general, findings have demonstrated that 
younger stage II and III CRC patients are much more likely to receive chemotherapy 
than older patients.55,61,64,65,67-72 Physicians may be more concerned when treating 
elderly patients because of their overall health status and issues with the toxicity of 
chemotherapeutic treatment. But, as discussed previously, treatment among elderly 
patients has been shown to be as effective with similar levels of toxicity when 
compared to younger patients.56,73 
 Many studies have shown that patients with multiple comorbidities are less 
likely than those with no or few comorbidities to receive chemotherapy 
treatment.55,61,64,65,67,68,70,71,74,75 Administrative databases often rely upon the 
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Charlson Comorbidity Index (CCI)76 or an adaptation of the CCI to capture the health 
status of the patient;77 however, particular comorbidities such as previous heart 
failure, chronic obstructive pulmonary disorder (COPD), diabetes or dementia have 
also been directly associated with decreased chemotherapy use among stage II and 
III CRC patients.74,75 
 Consistent with clinical guidelines, observational studies have also shown that 
characteristics of a patient’s tumor are strongly linked to the receipt of chemotherapy 
among stage II and III CRC patients. Cancer of the rectum vs. colon, stage III vs. II 
disease, less differentiated tumors, and less than 12 lymph nodes examined have all 
been associated with increased chemotherapy treatment(cite).   
 The Andersen conceptual model also emphasizes the role of enabling factors 
in the health services utilization. The availability and quality of health care personnel 
and facilities may be important enabling forces. However, few studies have been 
conducted on examining the influence of physician and hospital characteristics on a 
patient’s receipt of chemotherapy among stage II and III CRC. Only one study by 
Baldwin et al62 examined patient, physician, and hospital characteristics associated 
with the receipt of chemotherapy among stage III colon cancer patients in order to 
explain black-white differences. In unadjusted analysis, physicians who were 
younger, male, white, with fewer years of practice experience, having higher 
volumes of CRC consultations, working in solo practice, and being board certified in 
internal medicine were less likely to treat black patients with chemotherapy 
compared to white patients. Similarly, in unadjusted analyses, black patients were 
less likely to receive chemotherapy treatment at hospitals with higher hospital patient 
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volume, teaching affiliation, NCI cancer centers affiliation or Oncology group 
membership. However, after multivariate adjustment and accounting for clustering, 
the study reported that the majority of the black-white disparity in chemotherapy 
receipt was explained by patient characteristics and that physician and hospital 
characteristics contributed very little to the overall models.   
 A study by Keating et al71 surveyed physicians treating cancer patients and 
asked them about their recommendations for chemotherapy treatment according to 
age and comorbidity of patients. The authors also examined the influence of 
physician and practice characteristics on the administration of chemotherapy 
treatment. Overall, the study found that physicians varied in their recommendations 
for chemotherapy among older and sicker patients. Younger physician age was 
associated with an increased prevalence of treatment; however, other physician and 
practice characteristics did not strongly influence the treatment decision. Physician 
age would seem to be a proxy for length of time passed since medical school and 
residency training with the assumption that younger doctors were trained most 
recently and may be aware of the most recent evidence on chemotherapy treatment 
for elderly and those with multiple comorbidities.  
 
Patient, physician and hospital characteristics and the receipt of oxaliplatin among 
stage II and III CRC 
 Oxaliplatin was approved by the FDA for the adjuvant treatment of resectable 
stage III colon cancer in November 2004.34 As it is a relatively new treatment, there 
are few studies that have examined the patterns of oxaliplatin receipt in the routine 
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practice setting. Five studies were identified that have examined patient and/or 
physician characteristics associated with the receipt of oxaliplatin. These studies are 
summarized in Table 2.4 below. No studies have examined characteristics of the 
hospital where patients receive surgery and its influence on the receipt of oxaliplatin 
(similar to the study design of Baldwin et al62).    
 Two of these studies examined on-label use of oxaliplatin among individuals 
receiving chemotherapy. 58,70 The first study by Kahn et al was a population- and 
health system-based observational study examining adjuvant chemotherapy use and 
the occurrence of adverse events by age among 675 stage III colon cancer patients. 
Initial chemotherapy treatment was defined within the 6-months following surgical 
resection and assessed through medical record review. The second study by Hsiao 
et al utilized the SEER-Medicare database to compare the effectiveness and 
utilization trends of irinotecan and oxaliplatin regimens with those of 5-FU/LV among 
4,614 stage III colon cancer patients. In bivariate analysis, these studies found that 
older age was strongly associated with a decreased prevalence of oxaliplatin receipt. 
However, no further multivariate analysis was conducted investigating the 
associations between patient-level characteristics and the receipt of oxaliplatin.    
 A more recent study by Lund et al78 utilized the POC 2005 data to examine 
independent patient-level predictors for the receipt of oxaliplatin among a random 
sample of stage II/III CRC patients diagnosed in 2005. In 2005, 69% and 39% of 
CRC patients treated with chemotherapy in a SEER area received oxaliplatin for on- 
and off-label indications, respectively. Older age (65+ vs. <65) decreased the 
prevalence of both on- (prevalence ratio (PR)=0.47, 95% CI: 0.34, 0.64) and off-label 
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(PR=0.62, 95% CI: 0.45, 0.85) oxaliplatin use. For off-label indications, compared to 
patients diagnosed with stage II colon cancer, patients diagnosed with stage II 
(PR=0.37, 95% CI: 0.25, 0.55) and stage III (PR=0.70, 95% CI: 0.51, 0.95) rectal 
cancer were less likely to receive oxaliplatin. There was some evidence that 
Hispanics were less likely to receive oxaliplatin off-label as compared to White Non-
Hispanics (PR=0.71, 95% CI: 0.47, 1.07). In addition, regional variation was seen 
where individuals residing in the South and East had a lower prevalence of 
oxaliplatin treatment compared to those treated in the West.     
 Another study by Becker et al examined the role of both patient and physician 
characteristics in the receipt of oxaliplatin among stage III colon cancer patients.79 
This study was limited to 1,884 elderly individuals diagnosed with stage III colon 
cancer from September 2004-December 2005 using the SEER-Medicare database. 
Only 44% of the individuals in the analysis received chemotherapy and just over 
50% of them received oxaliplatin. The authors conducted a multivariate logistic 
regression using generalized estimating equations (GEE) to account for clustering 
by physician to examine patient and physician predictors of the receipt of oxaliplatin; 
however, their analysis included individuals who did not receive any chemotherapy 
treatment. Patient factors including younger age (OR=3.64, 95% CI: 2.38-5.57), 
white race (OR=1.93, 95% CI: 1.06-3.49), being married (OR=2.21, 95% CI: 1.60-
3.07), fewer comorbidities (OR=2.84, 95%: CI 1.81-4.45), urban location (OR=2.37, 
95% CI: 1.35-4.05), and moderate/poorly differentiated cancer (OR=2.47, 95% CI: 
1.30-4.67) were associated with the receipt of oxaliplatin. The only physician 
characteristic that had an influence on oxaliplatin receipt was having a younger 
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physician (OR=1.66, 95% CI: 1.12-2.46). The results of this study potentially mix the 
effects of patient and physician characteristics associated and overall chemotherapy 
receipt with the effects of these factors and the receipt of oxaliplatin (among a 
chemotherapy treated population).     
 A cross-sectional study by Abrams et al59 examined predictors of initiation of 
adjuvant chemotherapy in stage II and III colon cancer patients. This was the first 
study to report off-label patterns of oxaliplatin in stage II colon cancer. The study 
relied upon information from IntelliDose, an outpatient medical oncology practice 
ordering system for chemotherapy, and included 2,560 patients diagnosed from 
January 2004–April 2010. Treatment information was captured by physicians 
ordering specific chemotherapeutic agents and doses. This analysis was limited to 
individuals receiving chemotherapy and reported that older patients (80+ vs. <50: 
OR=0.05 (95% CI: 0.03, 0.09), those with diminished performance status (ECOG 2 
vs. 0: OR=0.34 (95% CI: 0.21, 0.56), and those treated in a private practice settings 
(OR=0.44 (95% CI: 0.27, 0.70) were significantly less likely to receive oxaliplatin. 
However, the authors were unable to examine the association between race, 
insurance coverage, socioeconomic status, and the number of lymph nodes 
examined, which are likely important factors in treatment selection.   
 
Rationale for Aim 2b: 
 Little research has focused on patterns of oxaliplatin use among stage II and 
III CRC. Of the existing studies, most have examined on-label use of oxaliplatin; 
however, off-label use is common and should be further investigated. Only two 
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studies have examined the influence of patient and physician characteristics in 
oxaliplatin treatment; however, these two studies included two different source 
populations, one that conditioned upon chemotherapy receipt and one that did not. 
Therefore, inconsistencies in the results may be due to a mixing of the effects of 
chemotherapy receipt and oxaliplatin receipt, specifically. It is possible to examine 
the role of hospital where a patient receives surgery and their influence on oxaliplatin 
receipt. Baldwin argued that even though chemotherapy is almost always 
administered in the outpatient setting, the characteristics of the hospital where 
surgery took place may influence chemotherapy receipt through the medical 
oncologists’ readmission of patients to the resection hospital, and therefore could 
represent a point of early education regarding the benefits of adjuvant 
chemotherapy.   
This dissertation addressed the above issues by examining the influence of 
patient, physician, and hospital characteristics on the receipt of oxaliplatin among 
stage II and III CRC patients and stratified analyses by cancer site and stage in 
order to examine patterns of off-label use.   
 
E. SUMMARY 
Significance of the study  
This study addressed two primary research questions.  The first aim provided 
updated information on the validity of Medicare claims to identify the initial course of 
chemotherapy treatment (including the specific agents administered) among patients 
diagnosed with a variety of cancers in 2000, 2002, and 2005. The second aims 
  29 
yielded detailed information about 1) the prevalence of treatment with specific 
chemotherapeutic agents for the treatment of stage II and III CRC and trends in their 
utilization from 2000-2007; and 2) the patient, physician, and hospital characteristics 
associated with the receipt of oxaliplatin treatment.    
These findings can be useful in three ways:  
Report updated validation information for researchers using the SEER-
Medicare data for chemotherapy-related research: Large healthcare databases 
are increasingly used to examine the dissemination and benefits and harms of 
chemotherapy treatment in routine practice, particularly among patients excluded 
from trials (e.g., the elderly). Misclassification of chemotherapy could bias estimates 
of frequency and association. An updated assessment of the work by Warren et al49 
is indicated as questions remain regarding the validity of Medicare claims to identify 
newly approved chemotherapeutic agents, the appropriate time window for 
assessment of initial chemotherapeutic treatment, and the validity of orally 
administered agents. This research can be used to assess the impact of potential 
misclassification in studies relying upon the SEER-Medicare linked database and to 
conduct sensitivity analyses which attempt to correct for such misclassification. 
Provide a more accurate picture of oxaliplatin utilization in the community: 
Drug utilization in routine clinical practice consists of both on- and off-label use. 
Oxaliplatin is currently approved by the FDA for the treatment of resectable stage III 
colon cancer, yet prior studies have shown that patients diagnosed with stage II 
colon and stage II and III rectal cancer frequently receive oxaliplatin as part of their 
initial course of treatment.78,79 Prior studies have generally focused on utilization 
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among patients treated primarily for metastatic disease at a small number of clinics, 
which may not reflect patterns of care in the larger community practice. Our study 
will be the first to assess on- and off-label use of oxaliplatin treatment in a large, 
population-based community practice setting.   
Inform targeted interventions to improve dissemination and appropriate use of 
oxaliplatin in clinical practice: Observational studies investigating the influence of 
patient, physician and hospital characteristics and the receipt of oxaliplatin are 
necessary to help elucidate the gap between the current state of knowledge based 
on RCT evidence and the reality of treating diverse populations in the community 
setting. Findings from these studies may highlight areas of potential overuse and 
underuse of oxaliplatin and may be helpful in developing targeted interventions to 
encourage more safe and equitable dissemination of treatment. 
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Table 2.1 Selected clinical trials of adjuvant chemotherapy in stage II and III colon cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Adapted from Rousseau 2010 
 
 
 
 
 
 
 
 
 
 
Trial N 
End 
Point Stage Trial Conclusions References 
INT-0035 929 OS III 5-FU/levamisole superior to observation Moertel et al 
NSABP C-04 2078 DFS, 
OS 
Dukes B/C 5 FU/LV superior to 5-FU/levamisole Wolmark et al 
INT-0089 3759 DFS   II and III Equivalency of 6 and 12 mo treatment 
cycles and of high dose vs. low dose LV 
Haller et al 
QUASAR 3239 OS II (92%) 5-FU/LV superior to observation Gray et al 
GERCOR C96 905 DFS Dukes 
B2/C 
Equivalency of LV5-FU2 and monthly 5-
FU/LV 
André et al 
X-ACT 1987 DFS III Capecitabine equivalency with LV5-FU 
bolus; less toxic 
Twelves et al 
MOSAIC 2246 DFS II and III FOLFOX4 superior to LV5-FU2 André et al 
NSABP C-07 2407 DFS II and III Bolus 5-FU/LV oxaliplatin (FLOX) superior 
to 5-FU/LV 
Kuebler et al 
NO16968 1886 DFS III Capecitabine plus oxaliplatin (XELOX) 
superior to standard bolus 5-FU/LV 
Haller et al 
CALGB 89803 1264 OS III No advantage for bolus IFL in stage III 
adjuvant CRC 
Saltz et al 
PETACC-3 3278 DFS II and III LV5-FU2  CPT11 not superior to LV5-FU2 Van Cutsem et al 
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Table 2.2 Selected clinical trials of adjuvant chemotherapy in stage II and III rectal cancer 
Trial N End 
Point 
Stage Trial Conclusions References 
NCCTG-864751 660 DFS II and III 5-FU during pelvic irradiation improved 
the effect of combined-treatment 
postoperative adjuvant therapy 
O'Connell et al 
INT-0114 1,696 DFS II and III No benefit of addition of leucovorin, 
levamisole, or both to 5-FU administered 
postoperatively 
Tepper et al 
SWOG-9304 1,917 DFS, 
OS 
II and III No DFS, OS or locoregional failure (LRF) 
benefit from adding leucovorin to 5-FU 
administered postoperatively  
 
Smalley et al 
German Rectal 
Cancer Study Group 
823 OS II and III Preoperative chemoradiotherapy vs. 
postoperative chemoradiotherapy 
improved local control and was associated 
with reduced toxicity 
Sauer et al 
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Table 2.3: Summary of observational studies chemotherapy treatment utilization among stage II and III CRC patients 
Author  
Data source 
N  
(age range) 
Cancer site 
and stage 
Years of 
analysis 
Type of 
chemotherapy Definition Results 
Potosky et al 
Patterns of 
Care Studies  
N=2,145 
20 years and 
older 
Stage II and III 
CRC 
1990, 
1991, 
1995 
5-FU, 5-FU + 
radiation therapy 
Re-abstraction of 
hospital records 
and physician 
verification of 
initial treatment 
planned or 
received 
Colon: 
* 5-FU prevalence of 
treatment was higher in 
stage III compared to II 
disease 
* Differences by age, 
younger patients having 
higher utilization 
Rectum: 
* Increase in RT + 
chemotherapy in 1989 
and decrease in RT alone 
* 5-FU prevalence +/- RT 
was higher in stage III 
compared to II disease 
Cronin et al 
Patterns of 
Care Studies 
N=827 in 2000 
20 years and 
older 
Stage III colon 
and stage II 
and III rectal 
cancer 
1987-
1991, 
1995, 
2000 
Guideline 
concordant 
treatment 
Stage III Colon:  
Adjuvant 5-FU  
 
Stage II/III Rectal: 
Adjuvant 5-FU + RT 
Re-abstraction of 
hospital records 
and physician 
verification of 
initial treatment 
planned or 
received 
Colon: 
* Guideline concordant 
treatment increased over 
time. 
* Older patients less likely 
to receive guideline 
concordant care 
Rectum: 
* Guideline concordant 
treatment increase for 
stage II rectal cancer, but 
decreased for stage III 
rectal cancer 
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Ferro et al 
Nationwide 
prospective 
registry of 
patients 
initiating 
chemotherap
y  
N=421 
21 - 97 years old 
Stage I - IV 
CRC (Over 
50% had 
mCRC) 
2002-2005 Focus on top 3 
utilized regimens: 
FOLFOX, 
IFL/FOLFIRI, and 5-
FU/LV 
Detailed case 
report form 
completed for 4 
cycles of 
chemotherapy 
Prevalence over the 
period: 
* 5-FU/LV (35%), IFL 
(26%), and FOLFOX 
(25%) 
Prevalence by year: 
* Oxaliplatin increased 
from 0% in 2002 to 61% in 
2005 
Hsiao et al 
SEER-
Medicare 
database 
N=4,615 
66 - >80 years 
old 
Stage III colon   2002-2005 5-FU/LV alone, 
Irinotecan-based 
regimen, 
Oxaliplatin-based 
regimen 
HCPCS codes in 
Medicare claims 
Prevalence by year: 2002-
2005 
5-FU: 32%, 32%, 21%, 
15% 
Irinotecan: 37%, 33%, 
16%, 14% 
Oxaliplatin (2004-2005): 
35%, 57%  
Abrams et al 
Outpatient 
medical 
oncology 
practices 
subscribing to 
the 
IntelliDose 
(Waltham, 
MA) 
N=2,560 
25-102 years old 
Stage II or III 
colon 
2004 - 
mid-2010 
FOLFOX/CapeOx, 
5-
FU/LV/capecitabine, 
bevacizumab 
Physicians 
entered specific 
chemotherapeutic 
agents and doses 
into ordering 
system 
Stage III:  
* In 2004, 39% were 
treated with oxaliplatin 
* In 2008, prevalence 
peaked at 91% 
Stage II: 
* In 2008, 79% were 
treated with oxaliplatin 
Stage II and III: 
* Bevacizumab use 
peaked at 12% in 2006 
and rapidly decreased 
after 
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Table 2.4: Summary of observational studies regarding patient and physician characteristics associated with oxaliplatin receipt among 
stage II and III CRC patients 
Author 
Data 
source 
N  
(age 
range) 
Cancer site 
and stage 
Years of 
analysis 
Type of 
chemotherapy Definition Patient-level results 
Physician-level 
results 
Kahn et al 
Cancer 
Care 
Outcomes 
Research 
and 
Surveillance 
(CanCORs) 
Study 
N=675 
18 - >80 
years 
old 
Stage III colon  2003-2005 Initial chemotherapy 
treatment classified 
as 
oxaliplatin-
containing,  
non–oxaliplatin-
containing, and 
unknown regimens. 
Chemotherapy 
was defined 
within 6 months 
after surgical 
resection 
and prior to any 
cancer 
recurrence using 
medical records 
*Among adjuvant 
chemotherapy users, 14 
(14%) of patients 75 
years and older and 178 
(44%) of younger 
patients used an 
oxaliplatin-containing 
regimen (difference, 
30%; 95% CI, 21%-
38%). 
na 
Hsiao et al 
SEER-
Medicare 
N=4,614 
66 - >80 
years 
old 
Stage III colon 
(all receiving 
chemotherapy) 
2002-2005 5-FU/LV alone, 
Irinotecan-based 
regimen, 
Oxaliplatin-based 
regimen 
HCPCS codes in 
Medicare claims 
* 17.6% (n=814) 
received oxaliplatin 
* Compared to patients 
66-69 years old, patients 
≥80 were less likely to 
receive oxaliplatin or 
irinotecan than younger 
patients (7.9% vs. 30%) 
na 
Lund et al 
Patterns of 
Care 
studies 
N=1,602 
20 
years 
and 
older 
Stage II and III 
CRC 
2005 Oxaliplatin agent 
receipt 
Re-abstraction of 
hospital records 
and physician 
verification of 
initial treatment 
planned or 
received 
* Older age (65+ vs. 
<65): 
 - On-label: PR=0.47 
(95% CI: 0.34, 0.64)  
 - Off-label PR=0.62 
(95% CI: 0.45, 0.85)  
 
* Off-label indications 
(compared to stage II 
colon cancer patients) 
 - Stage II rectal: 
PR=0.37 (95% CI: 0.25, 
0.55) 
 - Stage III: PR=0.70 
(95% CI: 0.51, 0.95) 
na  
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Becker et al 
SEER-
Medicare 
N=1,884 
65+ 
years 
old 
Stage III colon September 
2004 - 
December 
2005 
Oxaliplatin-
containing regimen 
HCPCS codes in 
Medicare claims 
* 44% received 
chemotherapy and only 
53.7% of them received 
oxaliplatin 
* Younger age: OR= 
3.64 (95% CI: 2.38-5.57) 
* White race: OR= 1.93 
(95% CI 1.06-3.49) 
* Being married: 
OR=2.21 (95% CI 1.60-
3.07) 
* Fewer comorbidities: 
OR=2.84 (95% CI: 1.81-
4.45) 
* Urban location: 
OR=2.37 (95% CI: 1.35-
4.05) 
* moderate/poorly 
differentiated cancer: 
OR=2.47 (95% CI: 1.30-
4.67) 
Younger 
physician: 
OR=1.66 (95% 
CI: 1.12-2.46) 
Abrams et 
al 
Outpatient 
medical 
oncology 
practices 
subscribing 
to the 
IntelliDose 
(Waltham, 
MA) 
N=2,560 
25-102 
years 
old 
Stage II or III 
colon (all 
receiving 
chemotherapy) 
2004 - 
mid-2010 
FOLFOX/CapeOx,  
5-
FU/LV/capecitabine, 
bevacizumab 
Physicians 
entered specific 
chemotherapeutic 
agents and doses 
into ordering 
system 
Stage II vs. II: OR=4.08 
(95% CI: 3.19, 5.21) 
50-59 vs. <50: OR=0.44 
(95% CI: 0.23, 0.82) 
60-69 vs. <50: OR=0.33 
(95% CI: 0.18, 0.60) 
70-79 vs. <50: OR=0.16 
(95% CI: 0.09, 0.29) 
80+ vs. <50: OR=0.05 
(95% CI: 0.03, 0.09) 
ECOG 2 vs. 0: OR=0.34 
(95% CI:0.21, 0.56)  
ECOG 1 vs. 0: OR=0.62 
(95% CI: 0.47, 0.82) 
NE vs. MW: OR=0.64 
(95% CI: 0.48, 0.87) 
Private vs. 
Academic: 
OR=0.44 (95% 
CI: 0.27, 0.70) 
> 18 vs. ≤ 6 
MAP: OR=1.46 
(95% CI: 1.02, 
2.11) 
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Predisposing Enabling Factors Illness level 
Demographic  
• Age, sex, marital status, 
past illness 
 
Social structure 
• Education, race, 
occupation, ethnicity 
 
Health beliefs 
• Attitudes towards illness, 
knowledge about disease 
Family 
• Household income, health 
insurance, access to 
regular care 
 
Community 
• Health care personnel, 
facility availability, region of 
the country, urban/rural 
location 
Perceived 
• Disability, symptoms, 
diagnoses, general state 
 
Evaluated 
• Symptoms, diagnoses 
Figure 2.1. The Behavioral Model of Health Services Use. Adapted from the Behavioral Model of Health 
Service Use by Andersen, Joana, et al., 1975 
  
 
 
 
 
 
CHAPTER 3 
 
METHODS 
 
 
This research consisted of two main components 1) an assessment of the utility 
of Medicare claims for capturing the receipt of any chemotherapy and specific agents 
delivered to patients diagnosed at age ≥65 with stage II or III colorectal cancer 
(CRC), in situ or early stage breast, non-small cell lung cancer (NSCLC), or ovarian 
cancer (Specific Aim 1), 2a) a description of trends in the utilization of specific 
chemotherapeutic agents for the treatment of stage II and III CRC (Specific Aim 2a), 
and 2b) an analysis of patient, physician, and hospital characteristics associated with 
the receipt of oxaliplatin from 2004-2007 (Specific Aim 2b). The methods that are 
common to both components will be described, followed by the methods specific to 
each component. Information from the SEER-Medicare linked database was used for 
all analyses. The University of North Carolina Public Health and Nursing Institutional 
Ethics Review Board approved the study protocol. 
 
A. DATA SOURCES  
 Data for this study were obtained from multiple databases linked through 
collaborative agreements between the National Cancer Institute (NCI), the Centers 
for Medicare and Medicaid Services (CMS), and the American Medical Association 
(AMA). 
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Surveillance, Epidemiology and End Results (SEER) Program  
(Specific aims 1, 2a, and 2b) 
The NCI’s Surveillance, Epidemiology, and End Results (SEER) program is an 
epidemiologic surveillance system collecting demographic information, clinical and 
tumor characteristics, initial surgical and radiation treatment, vital status, and cause 
of death for all individuals who are diagnosed with cancer and reside within one of 
the 17 SEER regions shown in Figure 3.1 below. These sites were selected based 
upon achieving the highest level of quality case ascertainment and reporting, and for 
their diverse sub-populations, making it one of the most relied-upon sources of 
national incidence and survival estimates. This program currently covers about 28% 
of the United States (US) and is comparable to the general US population across 
levels of poverty and education, but is slightly more urban and includes a greater 
proportion of foreign born residents.80,81  
 
Patterns of Care (POC) studies 
(Specific aim 1) 
NCI supplements the standard SEER registry abstraction to obtain detailed 
information about treatment for a subset of SEER cases. This effort, known as the 
POC, was developed by NCI to investigate the dissemination of state-of-the-art 
cancer treatment into community practices. These studies selected a stratified 
random sample of individuals (proportionate registry size) from the SEER program 
10, 12, and 13 cancer registries which covered up to 14% of the United States 
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population.82 All individuals were aged ≥20 years with a histologically confirmed 
cancer for selected sites, stages, and years. A listing of all cancers and stages 
examined by the POC are detailed elsewhere.83 Patients were excluded if the cancer 
diagnosis was determined at autopsy or on the death certificate; the diagnosis was a 
second malignancy other than to a non-melanoma skin cancer; or if the individual 
was simultaneously diagnosed with another cancer. Individuals were sampled by 
gender with oversampling of African-Americans and Hispanics in all years and 
Asian/Pacific Islanders and American Indians/Alaskan Natives in 2005 only.  
In addition to the standard SEER abstraction, the POC studies supplemented 
information on initial course of treatment by asking physicians (via mailed 
questionnaire) to verify the treatments delivered to patients; reviewing a unified 
medical record (inpatient and outpatient); and in some cases SEER registrars visited 
doctors’ offices to abstract data. Requested information included whether radiation, 
chemotherapy or immunotherapy was received as part of the initial course of 
treatment, identifying the specific agents delivered and the dates of first 
administration (2005 studies only).  
 
Surveillance, Epidemiology and End Results Program (SEER)–Medicare linked 
database 
(Specific aims 1, 2a, and 2b) 
The SEER-Medicare database consists of a linkage of two large population-
based data sources providing detailed clinical and healthcare utilization information 
on Medicare beneficiaries diagnosed with cancer.4 The SEER data (described 
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above) have been linked to Medicare enrollment and Part A (Hospital insurance) and 
B (Medical insurance) claims data. Approximately 93% of all elderly cancer patients 
in SEER have been matched to Medicare enrollment files with an established 
algorithm, resulting in a linked database that includes over 3.3 million elderly 
individuals (age ≥ 65 years).46 Nearly all Medicare beneficiaries are eligible for Part 
A and close to 93% opt to enroll in the Part B.47 
 
AMA Physician Masterfile 
(Specific aim 2b) 
 The AMA Physician Masterfile data contain current and historical information 
on over one million residents and physicians in the United States.84 To obtain 
characteristics of physicians providing services to patients in the SEER-Medicare 
database, we used the Universal Physician Identification Number (UPIN) to link 
claims from Medicare to the AMA data.85,86 
These data sources are uniquely situated for this research because of their large, 
longitudinal population-based structure and detailed data capture regarding patient-
level demographic, tumor, and clinical characteristics, general healthcare utilization, 
receipt of specific chemotherapeutic agents, and physician- and hospital-level 
characteristics. Figure 3.2 below provides a visual display of the study population 
created for Specific Aim 1. 
 
B. METHODS COMMON TO BOTH SPECIFIC AIMS 
i) SEER-Medicare data structure 
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For Medicare-eligible individuals with fee-for-service coverage and an incident 
cancer diagnosis in a SEER region, Medicare claims are organized into files 
including the Patient Entitlement and Diagnosis Summary File (PEDSF) and claims 
for inpatient hospitalizations (MEDPAR), durable medical equipment (DME), 
outpatient hospital services (OUTSAF), and physician and other provider services 
(NCH).49 The PEDSF includes one record for all individuals with a cancer diagnosis 
in a SEER area who have been matched with Medicare enrollment data. This file 
also includes basic demographic, clinical, tumor, and area level socioeconomic 
status measures. The claims files encompass a multitude of information on specific 
service dates, diagnoses, procedures, and agents delivered during medical 
encounters using various medical coding systems. Diagnoses and procedures on 
hospital claims are reported using International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9 CM) codes. ICD-9 CM diagnosis and 
procedure codes can be used to identify chemotherapy administration, but not 
specific agents. DME claims contain National Drug Codes (NDCs) that can be used 
to identify specific oral chemotherapeutic agents that are equivalent to other 
Medicare-covered intravenously administered chemotherapy agents.4 Physician and 
outpatient claims include ICD-9 CM diagnosis codes and Healthcare Common 
Procedure Coding System (HCPCS) codes. HCPCS can be used to identify 
chemotherapy and specific agents. Outpatient claims include revenue center codes 
which serve as another means of identifying chemotherapy administration. 
In addition, the NCI produces the Hospital file which reports descriptive 
information for hospitals that are part of the SEER-Medicare database.87 Hospital 
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data is derived from two sources maintained by CMS. Every year, hospitals that bill 
to Medicare are required to file an annual report called the Healthcare Cost Report 
(HCRIS). In addition, CMS occasionally requires hospitals to complete the Provider 
of Service (POS) survey. 
Additional information about these files as well as the numerous tables 
containing data summarizations and variable values will be discussed as relevant 
and can be found on the SEER-Medicare website 
(http://healthservices.cancer.gov/seermedicare/). 
ii) Data acquisition 
Through cooperation with the NCI, SEER registries, IMS, Inc., and Medical 
Marketing Solutions, Inc., we requested and received the following research files: 
Specific Aim 1 
a)  POC study data for in-situ or early stage breast cancer diagnosed in 2000 
and 2005, stage II or III CRC in 2000 and 2005, NSCLC in 2005, and ovarian 
cancer in 2002. This included a unique encrypted identifier that could be 
matched to the SEER-Medicare data; 
b) SEER-Medicare files (PEDSF, DME, MEDPAR, NCH, and OUTSAF) for the 
year prior, the year of, and the year following the POC study year for each 
cancer site listed above. 
Specific Aim 2 
a)  SEER-Medicare files (PEDSF, DME, MEDPAR, NCH, and OUTSAF) for all 
CRC patients diagnosed between 1999 and 2007, including claims files 
through 2008.  
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b) SEER-Medicare hospital files from 1996, 1998, and 2000-2009.  
c) AMA Physician Masterfile data for specified physicians treating patients with 
chemotherapy (discussed in detail below).          
iii) Definition of variables common to both Specific Aims 
• Age at diagnosis is reported as a continuous variable, but was categorized for 
analysis 65-69, 70-74, 75-79, 80-84, and 85+ years. 
• Diagnosis date is reported only as the month and year. No day of diagnosis is 
reported by SEER. Therefore, we assumed that all individuals were diagnosed 
on the first day of the month reported by SEER.  
• Sex is reported as male or female. 
• Race/ethnicity was reported by Medicare and will be categorized as follows: 
White Non-Hispanic, Black Non-Hispanic, Other Non-Hispanic, and Hispanic.  
• Marital status will be classified as either married, single, other (separated, 
divorced, widowed), or unknown.  
• Median household income (census tract) was reported by a linkage between 
the SEER data and the Census summary files for the year 2000 and will be 
reported in quartiles and with an unknown category.  
• Percentage living below the poverty line (census tract) was reported by a 
linkage between the SEER data and the Census summary files for the year 2000 
at the census-tract level and was categorized in quartiles.  
• Educational attainment (census tract) was reported by a linkage between the 
SEER registry data and the census summary files for the year 2000 and was 
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categorized as the percentage of individuals in a census tract receiving a high 
school education or higher.  
• Metropolitan county of residence was defined as either metropolitan or non-
metropolitan according to the SEER data. 
• Region reflected the census regions of Northeast, Midwest, South and West. 
• Year of diagnosis was reported from the SEER registry program. 
• Cancer site was defined as breast, colon, rectum, non-small cell lung, or ovary 
as reported by SEER data.  
• Tumor stage was reported according to the American Joint Commission on 
Cancer collaborative staging scheme 3rd Edition for cases diagnosed from 2000-
2003 and 6th Edition for cases diagnosed from 2004-2007.   
• Histological grade was grouped as well-differentiated/moderately differentiated, 
poorly/undifferentiated, or unknown, based upon pathology reports from the initial 
biopsy confirming the cancer diagnosis in the SEER data.  
• Tumor extent was reported as T1-T2, T3, or T4 based upon SEER data. 
• Tumor size was reported as < 2 cm, 2-3 cm, 3-4 cm, and >4 cm based upon 
SEER data.  
• Number of positive lymph nodes was reported for stage III patients only and 
be classified as none, 1-3 nodes, ≥ 4 nodes, positive but number unknown, or 
unknown or not stated. 
• Number of lymph nodes examined was classified as <12 nodes, ≥12 nodes, or 
unknown as reported by SEER.  
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• Metastasis was classified as Yes or No based on information obtained from the 
SEER data. 
• Comorbid conditions were captured by the using the ICD-9 codes associated 
with the 19 conditions included in the Charlson comorbidity scale, a weighted 
index measure of comorbidity that predicts 1-year all-cause mortality.76 The 
Klabunde adaptation was used to assess comorbidities in the 365 days prior to 
the diagnosis date.   
• Initial chemotherapeutic treatment regimen received will be defined using 
multiple claims files and their associated diagnosis, procedure, and drug codes 
and service dates. If a claim for a general chemotherapy procedure code, a 
diagnosis code for chemotherapy administration, or HCPCS code or NDC for a 
specific agent was found, the individual was defined as having received 
chemotherapy during the specified post-diagnosis period (2-12 months). The 
receipt of specific chemotherapy agents were defined similarly by identifying at 
least one claim with a HCPCS code or NDC for the specific agent during the 
post-diagnosis period. Appendix A lists all of the codes used to identify 
chemotherapy treatment in the Medicare claims.     
iii) Other methods common to both Specific Aims 
Analyses were conducted using SAS software version 9.2 (SAS Institute Inc, 
Cary, NC, USA).  
 
C. METHODS - SPECIFIC AIM 1 
i) Study group definition 
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The cancer sites, stages, and years of diagnoses were selected based on 
availability of the POC data and included in-situ or early stage breast cancer 
diagnosed in 2000 and 2005, stage II or III CRC in 2000 and 2005, NSCLC in 2005, 
and ovarian cancer in 2002. All POC patients were required to be age ≥65 at cancer 
diagnosis; and have POC treatment information verified through physician 
confirmation or a unified medical record review. Patients identified as being enrolled 
in a clinical trial were excluded because Medicare only covers routine costs 
associated with federally funded clinical trials (e.g, office visits and medical tests), 
and may not cover the cost of the agents themselves.70  
This study included eligible patients in the POC data who were matched to 
the SEER-Medicare data. Using the Medicare files, we required that all individuals 
were continuously enrolled in Medicare Parts A and B for the 2-, 4-, 6-, 8-, 10-, or 
12-month periods following diagnosis (the post-diagnosis periods); were never 
enrolled in a health maintenance organization (HMO) during the associated post-
diagnosis periods; did not have a subsequent cancer diagnosis (as reported by 
SEER) in the year following the qualifying POC cancer diagnosis; and had at least 
one Medicare claim during the specified post-diagnosis period. These criteria 
ensured that detailed claims for all individuals in the study were reported to Medicare 
and were not attributable to the treatment of a subsequent cancer. Due to the time-
varying nature of these criteria, the number of individuals eligible for analysis in each 
post-diagnosis period decreased over time. Details of the 6-month post-diagnosis 
cohort exclusions are listed in the Appendix B. 
ii) Definition of variables 
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Receipt of chemotherapy (POC data): For this analysis, the POC cohort was 
considered the gold standard measure for the receipt of any chemotherapy and for 
specific agents. Individuals were defined in POC as receiving any chemotherapy if a 
physician verified or a unified medical record identified that the individual was 
administered any chemotherapeutic agent. The receipt of specific agents was 
identified in POC through the same mechanism. For the POC studies conducted in 
2005, the date of first administration was collected for each specific agent delivered. 
Therefore, the analysis defined the initial course of treatment as the diagnosis date 
(set to the first day of the month, as only month of diagnosis is reported by SEER) to 
365 days following the diagnosis date. If treatment was received outside of the year 
following diagnosis, it was not considered part of the initial course of chemotherapy. 
Receipt of chemotherapy (SEER-Medicare data): Identifying the receipt of any 
chemotherapy and specific agents in Medicare claims required an examination of 
multiple claims files and their associated diagnosis, procedure, and drug codes and 
service dates. If a claim for a general chemotherapy procedure code, a diagnosis 
code for chemotherapy administration, or HCPCS code or NDC for a specific agent 
was found, the individual was defined as having received chemotherapy during the 
specified post-diagnosis period. The receipt of specific chemotherapy agents were 
defined similarly by identifying at least one claim with a HCPCS code or NDC for the 
specific agent during the post-diagnosis period. 
iii) Analysis 
Reporting of the agreement between the two data sources and the validity of 
chemotherapy captured in Medicare claims was examined at interval periods using 
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the 2, 4, 6, 8, 10 and 12-month post-diagnosis cohorts. Specifically, we estimated 
the Kappa and corresponding 95% CIs to assess concordance between the two data 
sources, as well as the sensitivity (Se), specificity (Sp), positive predictive value 
(PPV), and negative predictive value (NPV) and their corresponding 95% CIs of the 
Medicare claims definitions using the POC as the gold standard.       
We selected the specific chemotherapeutic agents to be validated based on 
their frequency of use in the 6-month post-diagnosis period. Using sample size 
calculations, we maximized the accuracy of the Se and Sp estimates to have a 
minimal acceptable lower confidence limit that is less than 10% from the point 
estimate.88 Based upon this sample size calculation, we included only specific 
chemotherapeutic agents where the POC reported that there were 37 or more 
individuals receiving the treatment. Due to the small number of in situ and early 
stage breast cancer patients receiving chemotherapy, the 2000 and 2005 POC data 
were combined for analysis.  
While the POC studies were considered the gold standard, they may be 
subject to measurement error in their reporting of initial chemotherapy treatment. 
Therefore, beyond reporting the Kappa to assess concordance between the two 
sources, we also conducted a sensitivity analysis to examine the impact of potential 
misclassification of the gold standard (i.e., the POC),89 focusing on an example of 
oxaliplatin receipt among stage II or III CRC patients diagnosed in 2005. 
 
D. METHODS – SPECIFIC AIM 2 
i) Study group definition – Prevalence of treatment and trends, 2000-2007  
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To examine trends in the utilization of specific chemotherapeutic agents, we 
first identified all patients in SEER diagnosed at age ≥66 with their first primary stage 
II or III cancer of the colon or rectum. SEER staging was based on the American 
Joint Commission on Cancer (AJCC), 3rd edition from January 1, 2000-December 
31, 2003 or AJCC 6th edition from January 1, 2004-December 31, 2007. The 
diagnosis date was set to the first day of the month, as SEER does not report the 
day of diagnosis. Diagnoses identified at autopsy or death certificate only were 
excluded, resulting in a cohort of 55,549 individuals. All individuals were required to 
have continuous Medicare Part A and B enrollment and no HMO enrollment for the 
12-months before and 8-months after diagnosis to ensure complete capture of 
healthcare utilization and treatment information. We excluded all individuals missing 
their month of diagnosis. As a result of these criteria, 32,278 individuals were eligible 
for further analysis. To examine the utilization of various chemotherapeutic agents, 
we restricted the cohort to individuals who had a claim for at least one specific 
chemotherapeutic agent in the 8-months following diagnosis, limiting our final cohort 
to 12,839 patients (Figure 4.1). 
ii) Study group definition – Oxaliplatin analysis, 2004-2007 
 To identify patient, physician, and hospital characteristics associated with the 
receipt of oxaliplatin, we first imposed identical SEER and Medicare criteria to 
construct the oxaliplatin cohort, limiting the diagnosis date to January 1, 2004–
December 31, 2007, the period where oxaliplatin began to disseminate among stage 
II and III CRC patients. This cohort included 15,694 patients.  
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Next, to identify characteristics of the hospital where cancer surgery was 
performed, we further restricted this cohort to individuals with a surgical claim (i.e., 
colectomy or proctectomy) in the inpatient (MEDPAR) or outpatient hospital 
(OUTSAF) files in the 6-months following diagnosis. These files include the provider 
number necessary to identify the hospital where treatment was received. If a patient 
had surgical claims from multiple hospitals, the first hospital was retained for 
analysis. We then linked the cohort to the SEER-Medicare Hospital file by the 
provider number and year of diagnosis for each patient. Hospitals that did not match 
and patients without claims for surgery during the 6-months post-diagnosis were 
excluded from analysis. The resulting cohort included 14,418 individuals and 1,022 
hospitals.  
Lastly, to identify characteristics of physicians providing chemotherapy 
services, we required all patients to have at least one claim for a specific 
chemotherapeutic agent in the physician (NCH) or the OUTSAF claims files during 
the 8-months following their diagnosis. For all patients, we obtained the performing 
and attending provider reported by the NCH and OUTSAF files, respectively.90 The 
physician with the most chemotherapy-related claims during the 8-month period 
post-diagnosis was considered the treating physician. UPINs that did not match to 
the AMA Physician Masterfile or contained all missing values were excluded from 
analysis. As a result, 4,819 patients, 795 hospitals, and 1,579 physicians were 
included in the final oxaliplatin analysis (Figure 4.2). 
iii) Definition of variables 
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Patient demographic characteristics: We obtained demographic characteristics of 
patients including year of diagnosis, sex, age at diagnosis (66-69, 70-74, 75-79, 80-
84, or 85+), race/ethnicity (White Non-Hispanic, Black Non-Hispanic, Other Non-
Hispanic, Hispanic, or Unknown), marital status (married, single, other (divorced, 
separated, widowed), or unknown), and region of residence (Northeast, South, 
Midwest, or West) from SEER. County-level metropolitan area was defined as 
metropolitan or non-metropolitan. SEER-Medicare does not report individual-level 
socioeconomic (SES) information. Therefore, we used the percentage of residents 
living below the federal poverty level, an aggregated measure of SES at the census 
tract level (Census 2000). Previous studies have shown that the census tract poverty 
variable may be the best proxy measure of economic status for elderly Medicare 
beneficiaries.91,92 This variable was categorized into quartiles: ≤4%, 4.01-≤8%, 8.01-
≤15%, and >15% (i.e., the tract with the highest percentage of people living below 
the poverty level). 
Tumor and clinical characteristics: We also obtained clinical characteristics from 
SEER, including cancer site (colon or rectum), AJCC stage (II or III), histologic grade 
(well/moderately differentiated, poorly/undifferentiated, or unknown), tumor size 
(<2cm, 2-<3cm, 3-<4cm, ≥4cm, or unknown), and number of lymph nodes examined 
(<12 nodes, ≥12 nodes, or unknown). The Charlson Comorbidity Index was 
measured from the 365 days of Medicare inpatient and outpatient claims prior to 
diagnosis using the methodology developed by Klabunde et al.77  
Hospital characteristics: We retrieved characteristics of hospitals where patients 
received colorectal cancer surgery from the SEER-Medicare Hospital file. Hospital 
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characteristics included NCI center designation (none, clinical, or comprehensive), 
NCI cooperative membership group count (0 or ≥1), teaching hospital status (yes or 
no), type of hospital (non-profit, private, or government), and total bed size, 
measured in quartiles (<204 beds, 204-343 beds, 344-487 beds, or 488+ beds).  
Physician characteristics: We obtained characteristics of physicians who treated 
patients with chemotherapy from the AMA Physician Masterfile and included medical 
degree (Medical Doctor (MD) or Doctor of Osteopathy (DO)), whether the physician 
was trained in the US (yes or no), year of medical school graduation (<1981 or 
≥1981), primary specialty (oncology, hematology/oncology, hematology, internal 
medicine, or other), and sex.   
Measurement of specific chemotherapeutic agents for the treatment of CRC: 
We categorized patients as receiving any chemotherapy treatment using 
International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) 
diagnosis, ICD-9-CM procedure, Current Procedural Terminology (CPT), and 
Healthcare Common Procedure Coding System (HCPCS), and revenue center 
codes. Because we were concerned with identifying initial treatment with 5-FU, 
capecitabine, oxaliplatin, irinotecan, and bevacizumab, specifically, we excluded 
patients with administration codes only, as we were unable to identify the agents 
they received. Initial treatment with these agents was defined using the two month 
period of claims data following the first chemotherapy claim for each patient. The 
administrative codes used to identify any chemotherapy, the specific agents, and 
their measures of validity using previously published methods49,93 are listed in the 
Appendix C. 
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v) Analysis 
We estimated the prevalence (and its 95% confidence interval (CI) of 1) any 
chemotherapy use among all eligible stage II and III CRC patients and 2) specific 
agents among all patients treated with chemotherapy (and having at least one 
specific agent claim) by year, cancer site, and stage. All analyses were performed 
on the chemotherapeutic agent-level so that individuals could be counted more than 
once in a given year (e.g., if they received both oxaliplatin and 5-FU). Therefore, the 
percentages do not sum to 100%. We present results for specific agents with ≥5% 
prevalence in at least one year. Logistic regression models stratified by cancer site 
and year were used to test for trends in the utilization of any chemotherapy from 
2000-2007 and for specific agents from 2004-2007. All models included patient age 
in 5-year categories (66-69, 70-74, 75-79, 80-84, 85+) to control for changes to the 
US population age structure over time, and diagnosis year to assess time trends.  
 Trends in the replacement of 5-FU with capecitabine were estimated by 
measuring the proportion of capecitabine use among all users of fluoropyrimidines 
by year, cancer site, and stage. Individuals receiving both 5-FU and capecitabine in 
the 2-months following their first chemotherapy claims were excluded from the 
analysis (n=83). Because the administrative definition for identifying capecitabine in 
Medicare claims has a very low sensitivity (47%), but high specificity (98%), we 
sought to estimate the proportion of patients receiving capecitabine that were 
missed by Medicare claims. The following equation was used to calculate the 
additional number of patients receiving capecitabine: 
Ncap_corr =(Ncap-(1-Secap)*(Nyr_tot- N5fu_tot)/(Secap+Spcap-1)94  
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Where Ncap_corr  is the number of capecitabine users, corrected for the 
misclassification in Medicare claims, Ncap is the number of capecitabine users 
identified by Medicare claims, Nyr_tot is the total number of individuals in site/stage 
patient group, N5fu_tot is the total number of 5-FU users in site/stage patient group, 
and Secap and Spcap are the sensitivity and specificity of the administrative definitions 
used to identify capecitabine in Medicare claims.   
 These additional patients were added to the total number of 5-FU and 
capecitabine users and the proportion of patients receiving 5-FU, capecitabine (as 
measured by claims), and capecitabine (as imputed using validation data) were 
graphed.     
 We estimated the proportion of patients receiving any chemotherapy and 
oxaliplatin, specifically, across patient demographic and clinical variables and 
calculated univariate prevalence ratios for the receipt of oxaliplatin for each patient, 
physician, and hospital characteristic.  
Patient observations for the oxaliplatin cohort were clustered within hospitals and 
physicians in a non-nested manner. Miglioretti and Heagerty have developed a 
generalized estimating equation (GEE) strategy that can be used to adjust for the 
correlation among observations within non-nested multi-level data and provide 
estimates of marginal (population-averaged) associations.95 We used this strategy to 
account for the correlations of oxaliplatin receipt among patients who were treated 
with chemotherapy by the same physician and/or underwent surgery at the same 
hospital. The patient was the unit of analysis and the hospital’s provider number and 
the physician’s UPIN were the clustering variables.  
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We estimated prevalence ratios for patient, physician and hospital variables 
using multivariate Poisson models with a log link and an independent GEE working 
matrix. Separate analyses for on- and off-label indications were performed, as the 
influence of the selected characteristics may vary by indication. Finally, we assessed 
the contribution of the measured patient, physician, and hospital characteristics on 
the explained variation in the receipt of oxaliplatin by calculating and comparing the 
c-statistic for four models, including: 1) all patient, physician and hospital variables, 2) 
patient-level variables only, 3) physician-level variables only, and 4) hospital-level 
variables only.  
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Source: National Cancer Institute, NIH Publication No. 05-4772 September 2005. 
Figure 3.1. Surveillance, Epidemiology and End Results (SEER) reporting areas and regions 
(left) and demographic comparison with the general population of the United States in 2000 
(right)  
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FIGURE 3.2 • Data sources utilized for chemotherapy validation 
study
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Figure 3.3: Flow chart for specific chemotherapeutic agent analysis  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SEER	Data 
All primary stage II and III CRC patients (66+) diagnosed between 
January 2000 and December 2007 
(n=55,549) 
Medicare	Enrollment 
Continuous Medicare Part A and B enrollment 
No HMO enrollment 
(12-month pre- and 8 months post-dx) 
(n=32,287) 
Medicare	Claims 
Claim for chemotherapy within 8-months of dx 
Claim for specific agent within 2-months of first chemo claim 
(n=12,839) 
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Figure 3.4: Flow chart for oxaliplatin analysis cohort 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All stage II and III CRC patients diagnosed 
between January 2004 and December 2007 
(n=26,479) 
Continuous Medicare Part A and B enrollment 
No HMO enrollment 
12-month pre- and 8-months post-dx 
(n=15,694) 
Claim for colectomy or proctectomy within 6-mo of 
dx 
(n=14,418) 
Physician UPIN match from claims data to AMA file 
(n=4,819 individuals, 795 hospitals, 1,579 
physicians) 
Claim for chemotherapy within 8-months of dx 
Claim for specific agent within 2-months of first chemo claim 
(n=4,913) 
  
 
 
 
 
 
CHAPTER 4 
 
RESULTS: Identifying specific chemotherapeutic agents in Medicare data: a 
validation study1 
 
A.  INTRODUCTION 
Chemotherapy represents an integral part of the treatment plan for many 
individuals diagnosed with cancer, as it decreases the risk of recurrence and 
mortality in many settings. Randomized controlled trials have documented the 
efficacy of chemotherapeutic agents used to treat a variety of cancers. To examine 
the translation of this evidence into the routine clinical setting, large healthcare 
databases, such as the Surveillance, Epidemiology, and End Results (SEER) 
program-Medicare linked database, are increasingly used to conduct non-
experimental studies evaluating the uses, benefits, and harms of these treatments 
among individuals excluded from trials, including older adults, those with multiple co-
morbidities, and those treated off-label.63,74,96-119    
   The validity of these studies relies upon a variety of issues, including the 
ability of claims data to accurately capture treatment(s) of interest, study endpoint(s), 
and other important design and clinical issues.48 Measurement error in the 
assessment of chemotherapy could lead to biased study results. Prior research 
supports the validity of claims data to identify intravenously administered 
                                                        
1 The results in this chapter have been accepted by Medicare Care on Sep 12, 2011. 
Authors include the committee members listed on the title page and Dr. Linda C. 
Harlan of the Applied Research Program at the National Cancer Institute. 
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chemotherapy treatment for a variety of cancer sites,49-53 but does not address more 
recently approved or orally administered agents, or changes in validity using multiple 
claims windows following diagnosis.   
We conducted a validation study to assess the utility of Medicare claims for 
capturing the receipt of any chemotherapy and specific agents delivered to patients 
diagnosed at age ≥65 with stage II or III colorectal cancer (CRC), in situ or early 
stage breast, non-small cell lung cancer (NSCLC), or ovarian cancer. This 
assessment 1) evaluated the validity of selected single agent chemotherapies, 
including an orally-administered agent and 2) described the variation in measures of 
validity for any chemotherapy and specific treatments over multiple follow-up periods 
and across cancer sites.     
 
 
B.  METHODS 
Data sources 
We used the National Cancer Institute (NCI)’s data from the Patterns of Care 
studies (POC) as the gold standard for identifying chemotherapy and the linked 
SEER-Medicare data as the test source for identifying chemotherapy. The SEER 
program of cancer registries collects demographic information, clinical and tumor 
characteristics, vital status, and cause of death for all incident cancers reported for 
individuals who reside in one of the registries’ defined geographic areas.2  
NCI supplements the standard SEER registry abstraction to obtain detailed 
information about treatment for a subset of SEER cases. This effort, known as the 
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POC, was developed by NCI to investigate the dissemination of state-of-the-art 
cancer treatment into community practices. These studies selected a stratified 
random sample of individuals (proportionate registry size) from the SEER program 
10, 12, and 13 cancer registries which covered up to 14% of the United States 
population.82 All individuals were aged ≥20 years with a histologically confirmed 
cancer for selected sites, stages, and years. A listing of all cancers and stages 
examined by the POC are detailed elsewhere.83 Patients were excluded if the cancer 
diagnosis was determined at autopsy or on the death certificate; the diagnosis was a 
second malignancy other than to a non-melanoma skin cancer; or if the individual 
was simultaneously diagnosed with another cancer. Individuals were sampled by 
gender with oversampling of African-Americans and Hispanics in all years and 
Asian/Pacific Islanders and American Indians/Alaskan Natives in 2005 only.  
In addition to the standard SEER abstraction, the POC studies supplemented 
information on initial course of treatment by asking physicians (via mailed 
questionnaire) to verify the treatments delivered to patients; reviewing a unified 
medical record (inpatient and outpatient); and in some cases SEER registrars visited 
doctors’ offices to abstract data. Requested information included whether radiation, 
chemotherapy or immunotherapy was received as part of the initial course of 
treatment, identifying the specific agents delivered and the dates of first 
administration (2005 studies only).  
The SEER-Medicare data arise from a linkage of persons in the SEER data 
with their Medicare enrollment, Part A (Hospital insurance) and B (Medical 
insurance) claims data. These data include approximately 3.3 million elderly 
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individuals (age ≥ 65 years) diagnosed with cancer in one of the SEER areas or 
regions.46 Approximately 94% of all elderly individuals included in SEER have been 
matched to the Medicare enrollment file with an established matching algorithm. 
Virtually 100% of all beneficiaries are eligible for Part A and 93% will opt to enroll in 
Part B.47  
For Medicare-eligible individuals with fee-for-service coverage, Medicare 
claims are organized into files including claims for inpatient hospitalizations, durable 
medical equipment (DME), outpatient hospital services, and physician and other 
provider services 49. These claims encompass a multitude of information on specific 
service dates, diagnoses, procedures, and agents delivered during medical 
encounters using various medical coding systems. Diagnoses and procedures on 
hospital claims are reported using International Classification of Diseases, Ninth 
Revision, Clinical Modification (ICD-9 CM) codes. ICD-9 CM diagnosis and 
procedure codes can be used to identify chemotherapy administration, but not 
specific agents. DME claims contain National Drug Codes (NDCs) that can be used 
to identify specific oral chemotherapeutic agents that are equivalent to other 
Medicare-covered intravenously administered chemotherapy agents.4 Physician and 
outpatient claims include ICD-9 CM diagnosis codes and Healthcare Common 
Procedure Coding System (HCPCS) codes. HCPCS can be used to identify 
chemotherapy and specific agents. Outpatient claims include revenue center codes 
which serve as another means of identifying chemotherapy administration. The 
codes used in our analysis are presented in the Appendix.    
Study sample and eligibility criteria 
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The cancer sites, stages, and years of diagnoses were selected based on 
availability of the POC data and included in-situ or early stage breast cancer 
diagnosed in 2000 and 2005, stage II or III CRC in 2000 and 2005, NSCLC in 2005, 
and ovarian cancer in 2002. All POC patients were required to be age ≥65 at cancer 
diagnosis; and have POC treatment information verified through physician 
confirmation or a unified medical record review. Patients identified as being enrolled 
in a clinical trial were excluded because Medicare only covers routine costs 
associated with federally funded clinical trials (e.g, office visits and medical tests), 
and may not cover the cost of the agents themselves.70  
This study included eligible patients in the POC data who were matched to 
the SEER-Medicare data. Using the Medicare files, we required that all individuals 
were continuously enrolled in Medicare Parts A and B for the 2-, 4-, 6-, 8-, 10-, or 
12-month periods following diagnosis (the post-diagnosis periods); were never 
enrolled in a health maintenance organization (HMO) during the associated post-
diagnosis periods; did not have a subsequent cancer diagnosis (as reported by 
SEER) in the year following the qualifying POC cancer diagnosis; and had at least 
one Medicare claim during the specified post-diagnosis period. These criteria 
ensured that detailed claims for all individuals in the study were reported to Medicare 
and were not attributable to the treatment of a subsequent cancer. Due to the time-
varying nature of these criteria, the number of individuals eligible for analysis in each 
post-diagnosis period decreased over time. Details of the 6-month post-diagnosis 
cohort exclusions are listed in the Appendix.   
   66 
Identification of receipt of chemotherapy and specific agents in POC and SEER-
Medicare       
For this analysis, the POC cohort was considered the gold standard measure 
for the receipt of any chemotherapy and for specific agents. Individuals were defined 
in POC as receiving any chemotherapy if a physician verified or a unified medical 
record identified that the individual was administered any chemotherapeutic agent. 
The receipt of specific agents was identified in POC through the same mechanism. 
For the POC studies conducted in 2005, the date of first administration was collected 
for each specific agent delivered. Therefore, the analysis defined the initial course of 
treatment as the diagnosis date (set to the first day of the month, as only month of 
diagnosis is reported by SEER) to 365 days following the diagnosis date. If 
treatment was received outside of the year following diagnosis, it was not considered 
part of the initial course of chemotherapy.  
Identifying the receipt of any chemotherapy and specific agents in Medicare 
claims required an examination of multiple claims files and their associated 
diagnosis, procedure, and drug codes and service dates. If a claim for a general 
chemotherapy procedure code, a diagnosis code for chemotherapy administration, 
or HCPCS code or NDC for a specific agent was found, the individual was defined 
as having received chemotherapy during the specified post-diagnosis period. The 
receipt of specific chemotherapy agents were defined similarly by identifying at least 
one claim with a HCPCS code or NDC for the specific agent during the post-
diagnosis period.  
Comparison of chemotherapy reported in POC and SEER-Medicare 
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Reporting of the agreement between the two data sources and the validity of 
chemotherapy captured in Medicare claims was examined at interval periods using 
the 2, 4, 6, 8, 10 and 12-month post-diagnosis cohorts. Specifically, we estimated 
the Kappa and corresponding 95% CIs to assess concordance between the two data 
sources, as well as the sensitivity (Se), specificity (Sp), positive predictive value 
(PPV), and negative predictive value (NPV) and their corresponding 95% CIs of the 
Medicare claims definitions using the POC as the gold standard.       
We selected the specific chemotherapeutic agents to be validated based on 
their frequency of use in the 6-month post-diagnosis period. Using sample size 
calculations, we maximized the accuracy of the Se and Sp estimates to have a 
minimal acceptable lower confidence limit that is less than 10% from the point 
estimate 88. Based upon this sample size calculation, we included only specific 
chemotherapeutic agents where the POC reported that there were 37 or more 
individuals receiving the treatment. Due to the small number of in situ and early 
stage breast cancer patients receiving chemotherapy, the 2000 and 2005 POC data 
were combined for analysis.  
While the POC studies were considered the gold standard, they may be 
subject to measurement error in their reporting of initial chemotherapy treatment. 
Therefore, beyond reporting the Kappa to assess concordance between the two 
sources, we also conducted a sensitivity analysis to examine the impact of potential 
misclassification of the gold standard (i.e., the POC),89 focusing on an example of 
oxaliplatin receipt among stage II or III CRC patients diagnosed in 2005.       
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 All analyses were conducted in SAS 9.2 (SAS Institute, Cary, NC). This study 
was reviewed by the University of North Carolina at Chapel Hill Institutional Review 
Board (IRB) and was determined to be exempt from IRB approval.  
 
 
C.  RESULTS  
The final validation cohort included 1,187 individuals diagnosed with a 
primary cancer of the breast in 2000 (n=156) or 2005 (n=155), colon or rectum in 
2000 (n=171) or 2005 (n=338), lung (non-small cell only) in 2005 (n=195), and ovary 
in 2002 (n=170) (Table 1). The percentage of patients receiving any chemotherapy 
in this cohort was 17% for in-situ/early stage breast cancer diagnosed in 2000 and 
20% in 2005; 61% for stage II/III CRC diagnosed in 2000 and 52% in 2005; 78% for 
ovarian cancer diagnosed in 2002; and 49% for NSCLC diagnosed in 2005.   
Figure 4.1 displays the sources of chemotherapy claims found in the 
Medicare files (hospital, physician, outpatient, DME, or multiple files) for all 
individuals included in the validation studies by cancer site and year of diagnosis. 
The large majority of individuals receiving chemotherapy only had claims reported in 
the physician file with very few individuals having claims identified in the hospital file 
only (< 3%). However, variation by cancer site and year of diagnosis was evident, 
reflecting different settings in which treatment was delivered by site and over time. 
For example, the approval of capecitabine in 2005 for CRC increased the 
percentage of individuals with claims identified using the DME file in 2005, as bills 
for orally administered agents appear primarily in the DME file. Chemotherapy 
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claims for breast cancer were largely identified by physician claims in both 2000 and 
2005.    
The comparisons of any chemotherapy identified by the POC and Medicare 
claims for the post-diagnosis periods for each cancer site/year are reported in Table 
4.2. Individuals receiving chemotherapy according to each data source is reported. 
Overall, the measures of agreement and validity for identifying the receipt of any 
chemotherapy were high for all cancer sites and post-diagnosis periods, except for 
the 2- and 4-month periods. Excluding those periods, Kappa estimates of 
concordance ranged from 77% - 87%; Se ranged from 84% - 97%, Sp ranged from 
78% - 97%, PPVs ranged from 87% - 96%, and NPVs ranged from 81% - 96%. The 
Sp estimates for the receipt of any chemotherapy for women diagnosed with ovarian 
cancer in 2002 were low in the later post-diagnosis periods. Due to the small number 
of women not receiving chemotherapy in the later post-diagnosis periods, the Sp 
estimates are unstable. Although the confidence intervals are wide, these intervals 
include Sp ranges that are consistent with estimates across other cancer sites. 
Across all cancer sites and year, the Sp and Se estimates for the receipt of any 
chemotherapy did not vary by patient characteristics (data not shown).  
Table 4.3 describes the measures of agreement and validity for the Medicare 
claims definitions used to identify the receipt of specific chemotherapeutic agents 
during the 6-month post-diagnosis period. For all intravenous agents administered to 
patients diagnosed with CRC and NSCLC, the measures of concordance and 
validity were high: Kappa ranged from 71% - 95%; Se ranged from 75% - 95%; Sp 
ranged from 90% - 99%; PPV ranged from 85% - 99%; and NPV ranged from 81% - 
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97%. Consistently, these measures (Kappa, Se, and PPV) were lowest for 
oxaliplatin. The measures of agreement and validity for identifying capecitabine, an 
orally administered agent equivalent to the intravenously administered 5-fluorouracil 
(5-FU) for CRC, in Medicare claims was poor with Kappa and Se of only 55% and 
47%, respectively.  
For breast cancer, the Se estimates for cyclophosphamide and doxorubicin 
were lower than other cancer site-agents at 75% and 73%, respectively; however, 
the 95% confidence intervals included values consistent with other sites. For ovarian 
cancer, the Sp estimates for carboplatin and paclitaxel were low at 78% and 74%, 
respectively. The Sp estimates for the specific ovarian cancer agents were lower 
than agents used to treat other cancer sites across all post-diagnosis periods (data 
not shown). Evidence of variation was seen when comparing the above measures 
for the same agents across different cancer sites. The Kappa, Se, and Sp for the 
receipt of paclitaxel and carboplatin were higher among patient treated for NSCLC 
as compared to those treated for ovarian cancer.   
Figure 4.2 illustrates how the use of multiple post-diagnosis periods changes 
the Se and Sp estimates for specific chemotherapeutic agents used to treat 
individuals diagnosed with stage II and III CRC in 2005. Generally, the Se for 
specific treatments reach their maximum close to the 8-month post-diagnosis period, 
with the exception of oxaliplatin for which Se continues to climb up to the 12-month 
post-diagnosis period. The Se of capecitabine is approximately 50% lower than the 
Se for all other CRC agents and remains steady over time. The Sp of Medicare 
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claims for identifying patients who did not receive specific CRC chemotherapy 
agents was > 93% for all post-diagnosis periods.  
We conducted a sensitivity analysis to assess the impact that potential 
misclassification of the gold standard (i.e., the POC studies) could have on our 
results, using the specific example of oxaliplatin treatment for CRC patients in 2005. 
We identified 10 individuals diagnosed with CRC in 2005 who had 2 or more claims 
for oxaliplatin during the 12-months post-diagnosis, but were not identified by POC 
as having received oxaliplatin as part of the initial course of treatment. Because 
physicians would not likely submit claims to Medicare for administering oxaliplatin 
(an expensive treatment) unless it was actually delivered, we assumed that these 
patients were misclassified by the POC studies. We varied the percentage of 
oxaliplatin-treated patients that were missed by the 2005 CRC POC study from 0% 
to 60% (or 0 to 6 individuals) and assessed the changes in Se, Sp, and PPV. Over 
the range of values, the PPV increased the most from 84% to 94%, while the Se and 
Sp remained nearly constant, increasing only from 89% to 90% and 96% to 98%, 
respectively (data not shown).   
 
 
D.  DISCUSSION 
We found that utilizing 6, 8, 10, or 12 months of Medicare claims following a 
primary diagnosis of in situ or early stage breast, stage II or III colorectal, non-small 
cell lung, or ovarian cancer can accurately identify whether an individual received 
any chemotherapy as part of their initial course of treatment. However, the ability of 
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Medicare claims to identify the receipt of specific chemotherapeutic agents appeared 
to vary by the agent, cancer site, and mode of administration. Medicare claims used 
to identify intravenously administered agents for CRC and NSCLC generally had a 
high Se, Sp, PPV, and NPV; although the Se tended to increase using longer post-
diagnosis periods for more recently approved agents (i.e., oxaliplatin). The Se and 
Sp estimates for identifying any chemotherapy treatment among individuals 
diagnosed with breast and ovarian cancers were generally lower than those for CRC 
and NSCLC. Across cancer sites, Medicare claims performed best when identifying 
specific agents used to treat NSCLC (i.e., carboplatin and paclitaxel) with all 
measures of agreement and validity exceeding 90%. 
Our findings update a prior study by Warren et al49 utilizing POC data (1991, 
1995, and 1996) to assess the utility of Medicare claims data for identifying the 
receipt of chemotherapy among individuals diagnosed with in situ or early stage 
breast, stage II or III CRC, and ovarian cancer. We found remarkably similar Kappa 
and Se estimates for identifying the receipt of any chemotherapy across cancer 
sites, with all confidence intervals encompassing the prior study estimates. However, 
our Kappa and Se estimates of Medicare claims for identifying specific 
chemotherapeutic agents are higher than those reported by Warren and colleagues. 
For example, in our study the Se of claims to identify the receipt of 
cyclophosphamide for the treatment of ovarian cancer was 75% (Table 3) compared 
with only 47% in the earlier study. It is possible that coding and reporting behavior 
improved over time, especially with the rising cost of chemotherapy.120 These 
updated measures further confirm the utility of Medicare claims to identify these 
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agents and provide the relevant information that may be used to correct for 
misclassification.    
Our study extended the Warren study by examining the chemotherapeutic 
agents that were not included in the original study, such as doxorubicin for breast 
cancer, oxaliplatin and capecitabine for CRC, and paclitaxel for breast and NSCLC. 
Another study examined the validity of Medicare claims for identifying specific 
agents in comparison to two different clinical trials among breast (1995-1997) and 
lung (1998-2000) cancer patients. The study reported the Se and Sp for doxorubicin 
as 91% (95% CI: 79%, 98%) and 100%, and for paclitaxel as 86% (79%, 92%) and 
100%, consistent with our findings.50  
This is the first study to examine the validity of Medicare claims to identify 
oxaliplatin for individuals diagnosed with stage II and III CRC. The Se of Medicare 
claims to identify oxaliplatin increases with the length of the claims window post-
diagnosis. A temporary HCPCS code was available for oxaliplatin (C9205) in 2005, 
while starting January 1, 2006, a permanent HCPCS code (J9263) was established. 
It is possible that physician coding improved after the permanent code was 
available, leading to better capture of oxaliplatin in later post-diagnosis periods.  
There have been no prior validation studies examining the reporting of 
capecitabine in the Medicare data. We observed consistently low Se estimates for 
capecitabine in the Medicare claims for all post-diagnosis periods. One possible 
explanation for its poor Se is that patients who cannot afford their copayments 
received the drug through pharmacy assistance programs sponsored by the 
pharmaceutical company. It may also be that patients had prescription drug 
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insurance that covered oral medications and the patient or the provider did not 
submit a claim for capecitabine to Medicare. Capecitabine is covered under 
Medicare Part B, as it is an oral alternative to an intravenous medication (5-FU). 
Chemotherapeutic agents that are only in oral form would be covered under 
Medicare’s Part D prescription drug coverage, which was implemented in 2006. 
Using  Part D data to identify use of oral chemotherapies is limited as only 52% of 
Medicare beneficiaries have Part D enrollment.121 Our findings, taken together with 
limited Part D enrollment among Medicare beneficiaries, suggest that the reporting 
of oral chemotherapeutic agents in the Medicare data may be incomplete. However, 
additional validation of oral chemotherapeutic agents in the Medicare data is 
needed. Two possible approaches to further explore the frequency of capecitabine 
claims in the outpatient drug setting would be to link: 1) Medicare dually-eligible 
individuals to their Medicaid prescription drug claims or 2) poor, elderly individuals 
that meet state pharmacy assistance program thresholds to their outpatient drug 
claims. These two groups are particularly unique and therefore results from these 
analyses may not be generalizable to the larger Medicare population.  
This study has a number of strengths. Through cooperation with the NCI and 
SEER registries, we linked verified treatment data obtained through physician 
confirmation or unified medical record review to Medicare claims for a large number 
of individuals aged ≥65 years and diagnosed with one of four different cancers. The 
detailed POC data collection allowed us to assess the validity of Medicare claims to 
identify specific agents that have not previously been validated. We examined and 
reported variation in measures of validity across different post-diagnosis periods, 
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whereas prior studies primarily used one or two broad post-diagnosis time 
windows.49,51,53  
Our study is not without limitations. There may be patients in the study who 
received treatment from another healthcare payer (e.g., the Veterans Health 
Administration). These claims would not be captured in this analysis. Therefore, our 
results may be viewed as minimum thresholds which could be improved by 
combining information from other payers. Furthermore, approximately 26% of 
individuals in the POC studies lacked physician confirmation or unified medical 
record review and were therefore excluded from analysis. We also excluded 
individuals who had any HMO enrollment during the post-diagnosis periods, as 
detailed claims data were not reported to Medicare for these individuals. These 
exclusions along with our focus on individuals 65+ years limit the overall 
generalizability of our findings. This analysis examined the receipt of chemotherapy 
as part of the initial course of treatment, but did not distinguish between adjuvant 
and neoadjuvant treatment; we would not expect results to differ based on the 
receipt of therapy before or after surgery, however. Similarly, we cannot be sure that 
claims appearing later in the post-diagnosis period still relate to the initial course of 
treatment, or whether they are actually linked to treatment of recurrent or 
progressive cancer.  
In conclusion, we assessed the utility of Medicare claims to identify the 
receipt of any chemotherapy and specific agents. Generally, Medicare claims can 
accurately identify the receipt of any chemotherapy and most specific agents 
administered intravenously. Medicare claims in combination with clinical data from 
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cancer registries may be a valuable resource for health services research focused 
on evaluating treatment-related issues. Additionally, these results may be useful to 
assess the potential impact of treatment misclassification in future studies.  
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Table 4.1. Characteristics of individuals aged 65 and older included in the Patterns of Care 
Studies* who were not enrolled in a clinical trial and had Medicare fee-for-service coverage 
only in the 6-month period following cancer diagnosis 
 
 Characteristic 
Breast 
(2000) 
Breast 
 (2005) 
Colo-
rectal 
(2000) 
Colo-
rectal 
(2005) 
Ovary 
(2002) 
Non-
Small 
Cell Lung 
(2005) 
(%)  
n=156 
(%) 
n=155  
(%) 
n=171 
(%) 
n=338 
(%) 
n=170 
(%) 
n=197 
Demographics 
  Gender 
    Male 0.0 0.0 46.8 43.5 0.0 50.8 
    Female 100 100 53.2 56.5 100 49.2 
  Age at diagnosis (mean, SD) 75 (7) 74 (7) 75 (7) 76 (8) 75 (7) 74 (6) 
  65 - 69 23.7 31.0 24.6 21.3 25.9 24.9 
  70 - 74 24.4 22.6 25.2 24.6 24.1 31.5 
  75 - 79 32.7 26.5 22.2 20.4 26.5 24.4 
  80 - 84 10.3 9.7 16.4 18.6 15.9 15.2 
  85+ 9.0 10.3 11.7 15.1 7.7 4.1 
  Race 
     White Non-Hispanic 53.2 42.6 54.4 50.3 70.0 46.2 
     Black Non-Hispanic 21.2 24.5 14.6 17.8 16.5 23.4 
     Hispanic 13.5 18.1 13.5 14.8 4.1 12.7 
     Other 12.2 13.6 17.5 17.2 9.4 16.8 
     Unknown 0.0 1.3 0.0 0.0 0.0 1.0 
  Marital status 
    Married 43.6 43.2 53.8 54.7 54.1 53.3 
    Other 53.2 54.8 45.0 44.1 44.1 46.2 
    Unknown 3.2 1.9 1.2 1.2 1.8 0.5 
  Median household income† 
   ≤ $30,000 26.3 21.9 16.96 26.0 26.5 17.3 
  $30,001 - $45,000 31.4 25.8 32.75 26.3 26.5 36.0 
  $45,001 - $60,000 25.0 28.4 24.56 21.3 22.9 21.8 
  ≥ $60,001 17.3 23.9 25.73 26.3 24.1 24.9 
  High school education† 
    ≤ 70% 17.3 22.58 22.22 24.3 16.5 21.3 
    71 - 80% 18.6 20.65 16.37 14.2 18.8 18.8 
    81 - 90% 40.4 29.68 32.75 32.3 34.1 37.6 
    > 90% 23.7 27.1 28.65 29.3 30.6 22.3 
  County of residence in metro 
areas size† 
    Over 1 million population 42.3 61.3 63.2 63.3 48.2 52.3 
    250,000 - 1 million population 25.0 23.9 20.5 15.4 23.5 28.4 
    All other counties 32.7 14.8 16.4 21.3 28.2 19.3 
       
Tumor characteristics at diagnosis 
  Histologic grade 
    Well-differentiated 16.0 18.7 2.9 5.9 5.9 4.6 
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    Moderately differentiated 36.5 43.9 67.3 66.9 12.9 23.4 
    Poorly/undifferentiated 32.1 27.1 28.3 26.2 48.8 32.5 
    Unknown 15.4 10.3 1.2 1.2 32.4 39.6 
  Tumor extent 
    Tis 23.1 23.9 0.0 0.0 0.0 0.0 
    T1 48.1 41.9 1.2 2.1 25.3 24.9 
    T2 24.4 29.0 5.3 5.0 18.8 32.0 
    T3 2.6 4.5 75.4 79.0 34.7 8.1 
    T4 0.0 0.0 18.1 13.9 0.0 24.4 
    Unknown 1.9 0.7 0.0 0.0 21.2 10.7 
  Metastasis 
    No 100.0 100 100 100 78.8 70.1 
    Yes 0.0 0.0 0.0 0.0 21.2 29.4 
    Unknown 0.0 0.0 0.0 0.0 0.0 0.5 
  Number of positive lymph nodes 
    None 50.0 43.9 40.4 52.4 25.3 27.4 
    1 - 3 nodes 10.3 23.2 36.3 30.8 8.2 5.6 
    ≥ 4 nodes 8.3 9.1 15.8 11.2 0.6 2.6 
    Positive but number unknown 0.0 0.0 1.2 0.0 0.6 1.5 
    Unknown or nodes not 
examined 31.4 23.9 6.4 5.6 65.3 63.0 
* POC studies in 2000, 2002, and 2005 include the SEER 10, SEER 12, and SEER 13 registries, 
respectively. 
† Median household income, percentage of census tract with a high school education, and county of 
residence in metro area size are linked from 2000 Census data. 
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Table 4.2: Comparison of any chemotherapy identified by SEER POC data and Medicare claims during various post-diagnosis periods 
for selected cancer sites and year 
 
 
Source reporting receipt of chemotherapy 
     
  
POC=Yes, 
Med=Yes 
POC=No, 
Med=No 
POC=Yes, 
Med=No 
POC=No, 
Med=Yes 
Kappa (%)  
(95% CI) 
Se (%) 
(95% CI) 
Sp (%) 
 (95% CI)† 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
Breast (2000, 2005) 
         
  2 months  11 259 46 2 27 (7, 46) 19 (10, 32) 99 (97, 100) 85 (55, 98) 85 (80, 89) 
  4 months  45 252 13 6 79 (70, 88) 78 (65, 87) 98 (95, 99) 88 (76, 96) 95 (92, 97) 
  6 months  48 247 9 7 83 (74, 91) 84 (72, 93) 97 (94, 99) 87 (76, 95) 96 (93, 98) 
  8 months  48 245 7 7 84 (77, 92) 87 (76, 95) 97 (94, 99) 87 (76, 95) 97 (94, 99) 
  10 months  48 240 7 8 83 (75, 92) 87 (76, 95) 97 (94, 99) 86 (74, 94) 97 (94, 99) 
  12 months  49 240 6 8 85 (77, 93) 89 (78, 96) 97 (94, 99) 86 (74, 94) 98 (95, 99) 
          
Colorectal (2000) 
         
  2 months  45 78 61 3 36 (23, 49) 42 (33, 52) 96 (90, 99) 94 (83, 99) 56 (47, 65) 
  4 months  90 66 15 6 76 (66, 86) 86 (78, 92) 92 (83, 97) 94 (87, 98) 81 (71, 89) 
  6 months  92 60 12 7 77 (67, 87) 88 (81, 94) 90 (80, 96) 93 (86, 97) 83 (73, 91) 
  8 months  93 53 8 8 79 (69, 89) 92 (85, 97) 87 (76, 94) 92 (85, 97) 87 (76, 94) 
  10 months  91 50 7 8 79 (69, 89) 93 (86, 97) 86 (75, 94) 92 (85, 96) 88 (76, 95) 
  12 months  88 48 7 10 76 (65, 87) 93 (85, 97) 83 (71, 91) 90 (82, 95) 87 (76, 95) 
          
Colorectal (2005) 
         
  2 months  70 172 115 3 36 (26, 45) 38 (31, 45) 98 (95, 100) 96 (88, 99) 60 (54, 66) 
  4 months  145 157 34 8 76 (69, 83) 81 (74, 86) 95 (91, 98) 95 (90, 98) 82 (76, 87) 
  6 months  154 151 23 10 81 (74, 87) 87 (81, 92) 94 (89, 97) 94 (89, 97) 87 (81, 91) 
  8 months  153 145 19 10 82 (76, 88) 89 (83, 93) 94 (88, 97) 94 (89, 97) 88 (83, 93) 
  10 months  148 144 17 10 83 (77, 89) 90 (84, 94) 94 (88, 97) 94 (89, 97) 89 (84, 94) 
  12 months  147 140 15 9 85 (79, 90) 91 (85, 95) 94 (89, 97) 94 (89, 97) 90 (85, 94) 
 
         
Non-Small Cell Lung (2005) 
        
  2 months  61 149 60 5 50 (39, 60) 50 (41, 60) 97 (93, 99) 92 (83, 97) 71 (65, 77) 
  4 months  95 111 17 6 80 (72, 88) 85 (77, 91) 95 (89, 98) 94 (88, 98) 87 (80, 92) 
  6 months  89 95 8 5 87 (80, 94) 92 (84, 96) 95 (89, 98) 95 (88, 98) 92 (85, 97) 
  8 months  77 87 8 5 85 (78, 93) 91 (82, 96) 95 (88, 98) 94 (86, 98) 92 (84, 96) 
  10 months  70 76 6 4 87 (79, 95) 92 (84, 97) 95 (88, 99) 95 (87, 99) 93 (85, 97) 
  12 months  64 72 5 6 85 (76, 94) 93 (84, 98) 92 (84, 97) 91 (82, 97) 94 (85, 98) 
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Ovary (2002)* 
         
  2 months  96 45 48 3 46 (33, 59) 67 (58, 74) 94 (83, 99) 97 (91, 99) 48 (38, 59) 
  4 months  129 36 9 6 77 (66, 88) 93 (88, 97) 86 (71, 95) 96 (91, 98) 80 (65, 90) 
  6 months 125 32 5 5 83 (72, 93) 96 (91, 99) 86 (71, 95) 96 (91, 99) 86 (71, 95) 
  8 months  119 26 6 6 76 (64, 89) 95 (90, 98) 81 (64, 93) 95 (90, 98) 81 (64, 93) 
  10 months  112 25 5 6 77 (64, 90) 96 (90, 99) 81 (63, 93) 95 (89, 98) 83 (65, 94) 
  12 months  109 21 3 6 78 (65, 92) 97 (92, 99) 78 (58, 91) 95 (89, 98) 88 (68, 97) 
POC = Patterns of Care, Med=Medicare, Se = Sensitivity, Sp = Specificity, PPV = Positive predictive value, NPV = Negative predictive value 
* Three ovarian cancer patients did not report any chemotherapy treatment data in POC and were removed from analysis.  
† Exact binomial 95% confidence intervals are rounded to the nearest digit. Therefore, none of the upper limits is exactly 100%.  
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Table 4.3: Comparison of specific chemotherapeutic agents identified by SEER POC data and Medicare claims during the 6-month post-
diagnosis period for selected cancer sites and years* 
 
 
Source reporting receipt of specific agent   
    
  
POC=Y 
Med=Y 
POC=N 
Med=N 
POC=Y 
Med=N 
POC=N 
Med=Y 
Kappa 
(%) 
(95% CI) 
Se (%) 
(95% CI) 
Sp (%)  
(95% CI)† 
PPV (%) 
(95% CI)† 
NPV (%) 
(95% CI) 
Breast (2000 and 2005) 
         
  Cyclophosphamide 39 249 13 4 83 (73, 92) 75 (61, 86) 98 (96, 100) 91 (78, 97) 95 (92, 97) 
  Doxorubicin 27 266 10 3 78 (67, 90) 73 (56, 86) 99 (97, 100) 90 (73, 98) 96 (93, 98) 
          
Colorectal (2000) 
         
  5-Fluorouracil (5-FU) 87 62 15 5 76 (66, 86) 85 (77, 92) 93 (83, 98) 95 (88, 98) 81 (70, 89) 
          
Colorectal (2005) 
         
  5-Fluorouracil (5-FU) 114 192 14 11 83 (77, 89) 89 (82, 94) 95 (91, 97) 91 (85, 96) 93 (89, 96) 
  Capecitabine 22 279 25 5 55 (39, 70) 47 (32, 62) 98 (96, 99) 81 (62, 94) 92 (88, 95) 
  Oxaliplatin 51 254 17 9 73 (63, 82) 75 (63, 85) 97 (94, 98) 85 (73, 93) 94 (90, 96) 
          
Non-Small Cell Lung (2005) 
         
  Carboplatin 77 112 4 1 95 (90, 99) 95 (88, 99) 99 (95, 100) 99 (93, 100) 97 (91, 99) 
  Paclitaxel 61 123 7 2 90 (83, 96) 90 (80, 96) 98 (94, 100) 97 (89, 100) 95 (89, 98) 
          
Ovary (2002) 
         
  Carboplatin 110 35 11 10 68 (56, 81) 91 (84, 95) 78 (63, 89) 92 (85, 96) 76 (61, 87) 
  Paclitaxel 100 39 13 14 62 (49, 75) 88 (81, 94) 74 (60, 85) 88 (80, 93) 75 (61, 86) 
POC = Patterns of Care, Med=Medicare, Se = Sensitivity, Sp = Specificity, PPV = Positive predictive value, NPV = Negative predictive value 
* Individuals lacking treatment data for the specific agent of interest were excluded from analysis. 
† Exact binomial 95% confidence intervals are rounded to the nearest digit. Therefore, none of the upper limits is exactly 100%.  
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Figure 4.1. Sources of chemotherapy claims for the year following diagnosis reported by 
Medicare for all individuals aged ≥65 years in the POC studies, by selected cancer site and 
year of diagnosis.  
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Figure 4.2. Sensitivity and specificity of Medicare claims for identifying the receipt of specific 
agents by post-diagnosis period, Colorectal cancer, 2005.  
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CHAPTER 5 
 
RESULTS: Influence of patient, physician, and hospital characteristics on the 
receipt of oxaliplatin among elderly stage II and III colorectal cancer patients2 
 
A.  INTRODUCTION 
In 2010, there were an estimated 142,570 newly diagnosed cases and 51,370 
deaths attributable to colorectal cancer (CRC) in the United States (US), leading to 
approximately $8.9 billion in spending on cancer care.2,3 Almost 50% of these cases 
were diagnosed at stage II or III, representing a large portion of the overall disease 
burden.8 Treatment guidelines for stage II and III CRC have changed over time, 
incorporating new evidence on therapies evaluated in randomized controlled trials 
(RCTs).122  
Chemotherapy represents an integral part of the treatment plan for many 
individuals diagnosed with CRC as it is proven to decrease the risk of disease 
recurrence and overall mortality.12-19 Until the early 2000’s, the National 
Comprehensive Cancer Network (NCCN) recommended that stage III colon and 
stage II and III rectal cancer patients receive a chemotherapy regimen of 5-
fluorouacil (5-FU) plus leucovorin (LV). However, RCTs in the mid-2000’s sought to 
establish the efficacy of a number of new chemotherapeutic agents used to treat 
CRC. In particular, three RCTs demonstrated that adding oxaliplatin to 5-FU/LV 
significantly improved disease-free and overall survival for individuals diagnosed 
                                                        
2 This chapter will be submitted the journal, Cancer. Authors include those listed on 
the title page. 
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with stage III, but not stage II colon cancer.13,23,24,41 Clinically significant toxicities of 
oxaliplatin treatment included neutropenia and sensory neuropathy.  Based on an 
evaluation of the evidence on benefit and harm, the Food and Drug Administration 
(FDA) approved oxaliplatin for the treatment of stage III colon cancer in November 
200434 and it has now become the standard of care in this group.10  
While many stage II CRC patients receive chemotherapy, the benefits of 
treatment are controversial. Although RCTs of chemotherapy in stage II disease 
have shown a trend towards efficacy of 5-FU/LV treatment alone36 and in 
combination with oxaliplatin,13,23,41 the differences have not lead to significant 
survival benefits. Among high-risk stage II colon cancer patients, such as those with 
T4 tumor penetration, poorly differentiated histology, bowel obstruction, bowel 
perforation, or fewer than 12 lymph nodes examined, studies suggest that adjuvant 
therapy with 5-FU/LV (alone or in combination with oxaliplatin) may be 
beneficial.13,123 RCT evidence is lacking on the benefits of oxaliplatin for stage II and 
III rectal cancer in preoperative chemoradiotherapy regimens; however, results from 
colon cancer are often extrapolated to support its use in patients with rectal cancer.    
Despite this uncertainty in the benefit of newer chemotherapeutic agents, 
particularly among the elderly who were underrepresented in RCTs, few studies 
have examined the utilization patterns of specific chemotherapeutic agents in stage 
II and III CRC or the translation of the trial evidence on oxaliplatin into routine clinical 
practice. Similarly, little is known about the off-label use of oxaliplatin in patients 
diagnosed with stage II colon or stage II or III rectal cancers. The objectives of the 
current study were to describe trends in the utilization of specific chemotherapeutic 
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agents for the treatment of stage II and III CRC (5-flurouracil, capecitabine, 
oxaliplatin, irinotecan, and bevacizumab) from 2000-2007 and identify patient, 
physician, and hospital characteristics associated with the receipt of oxaliplatin from 
2004-2007. We examined the influence of these characteristics overall and 
separately for on- and off-label indications. In light of the clinical trial evidence, our 
findings highlight areas of potential overuse and underuse of specific 
chemotherapeutic agents and may be helpful in developing targeted interventions to 
encourage more evidence-based and equitable dissemination of effective 
treatments.  
 
 
B.  METHODS 
Data sources 
 Data for this study were obtained from multiple databases linked through 
collaborative agreements between the National Cancer Institute (NCI), the Centers 
for Medicare and Medicaid Services (CMS), and the American Medical Association 
(AMA). 
 
Surveillance, Epidemiology and End Results Program (SEER)–Medicare 
database 
The SEER-Medicare database consists of a linkage of two large population-
based data sources providing detailed clinical and healthcare utilization information 
on Medicare beneficiaries diagnosed with cancer.4 The SEER registries collect 
demographic, clinical and tumor characteristics, vital status, and cause of death for 
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all incident cancers reported for individuals who reside in one of the registries’ 
defined geographic areas, currently covering approximately 28% of the US 
population.45 These data have been linked to Medicare enrollment and Part A 
(Hospital insurance) and B (Medical insurance) claims data. Approximately 93% of 
all elderly cancer patients in SEER have been matched to Medicare enrollment files 
with an established algorithm, resulting in a linked database that includes over 3.3 
million elderly individuals (age ≥ 65 years).46 Nearly all Medicare beneficiaries are 
eligible for Part A and close to 93% opt to enroll in the Part B.47 
In addition, the NCI produces the Hospital file which reports descriptive 
information for hospitals that are part of the SEER-Medicare database.87 Hospital 
data is derived from two sources maintained by CMS. Every year, hospitals that bill 
to Medicare are required to file an annual report called the Healthcare Cost Report 
(HCRIS). Additionally, CMS periodically requests institutions to complete the 
Provider of Service (POS) survey for certification purposes. NCI has extracted 
selected variables from the two data sources from 1996, 1998, and 2000-2009 for 
inclusion in the Hospital File. Medicare inpatient and outpatient hospital claims can 
be linked to the Hospital file using the provider number on the claim.  
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AMA Physician Masterfile 
 The AMA Physician Masterfile data contain current and historical information 
on over one million residents and physicians in the United States.84 To obtain 
characteristics of physicians providing services to patients in the SEER-Medicare 
database, we used the Universal Physician Identification Number (UPIN) to link 
claims from Medicare to the AMA data.85,86  
Study cohorts 
Specific agent trends cohort 
 To examine trends in the utilization of specific chemotherapeutic agents, we 
first identified all patients in SEER diagnosed at age ≥66 with their first primary stage 
II or III cancer of the colon or rectum. SEER staging was based on the American 
Joint Commission on Cancer (AJCC), 3rd edition from January 1, 2000-December 
31, 2003 or AJCC 6th edition from January 1, 2004-December 31, 2007. The 
diagnosis date was set to the first day of the month, as SEER does not report the 
day of diagnosis. Diagnoses identified at autopsy or death certificate only were 
excluded, resulting in a cohort of 55,549 individuals. All individuals were required to 
have continuous Medicare Part A and B enrollment and no HMO enrollment for the 
12-months before and 8-months after diagnosis to ensure complete capture of 
healthcare utilization and treatment information. We excluded all individuals missing 
their month of diagnosis. As a result of these criteria, 32,278 individuals were eligible 
for further analysis. To examine the utilization of various chemotherapeutic agents, 
we restricted the cohort to individuals who had a claim for at least one specific 
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chemotherapeutic agent in the 8-months following diagnosis, limiting our final cohort 
to 12,839 patients.            
Oxaliplatin cohort 
 To identify patient, physician, and hospital characteristics associated with the 
receipt of oxaliplatin, we first imposed identical SEER and Medicare criteria to 
construct the oxaliplatin cohort, limiting the diagnosis date to January 1, 2004–
December 31, 2007, the period where oxaliplatin began to disseminate among stage 
II and III CRC patients. This cohort included 15,694 patients.  
Next, to identify characteristics of the hospital where cancer surgery was 
performed, we further restricted this cohort to individuals with a surgical claim (i.e., 
colectomy or proctectomy) in the inpatient (MEDPAR) or outpatient hospital 
(OUTSAF) files in the 6-months following diagnosis. These files include the provider 
number necessary to identify the hospital where treatment was received. If a patient 
had surgical claims from multiple hospitals, the first hospital was retained for 
analysis. We then linked the cohort to the SEER-Medicare Hospital file by the 
provider number and year of diagnosis for each patient. Hospitals that did not match 
and patients without claims for surgery during the 6-months post-diagnosis were 
excluded from analysis. The resulting cohort included 14,418 individuals and 1,022 
hospitals.  
Lastly, to identify characteristics of physicians providing chemotherapy 
services, we required all patients to have at least one claim for a specific 
chemotherapeutic agent in the physician (NCH) or the OUTSAF claims files during 
the 8-months following their diagnosis. For all patients, we obtained the performing 
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and attending provider reported by the NCH and OUTSAF files, respectively.90 The 
physician with the most chemotherapy-related claims during the 8-month period 
post-diagnosis was considered the treating physician. UPINs that did not match to 
the AMA Physician Masterfile or contained all missing values were excluded from 
analysis. As a result, 4,819 patients, 795 hospitals, and 1,579 physicians were 
included in the final oxaliplatin analysis.  
Patient characteristics 
 We obtained demographic characteristics of patients including year of 
diagnosis, sex, age at diagnosis (66-69, 70-74, 75-79, 80-84, or 85+), race/ethnicity 
(White Non-Hispanic, Black Non-Hispanic, Other Non-Hispanic, Hispanic, or 
Unknown), marital status (married, single, other (divorced, separated, widowed), or 
unknown), and region of residence (Northeast, South, Midwest, or West) from 
SEER. County-level metropolitan area was defined as metropolitan or non-
metropolitan. SEER-Medicare does not report individual-level socioeconomic (SES) 
information. Therefore, we used the percentage of residents living below the federal 
poverty level, an aggregated measure of SES at the census tract level (Census 
2000). Previous studies have shown that the census tract poverty variable may be 
the best proxy measure of economic status for elderly Medicare beneficiaries.91,92 
This variable was categorized into quartiles: ≤4%, 4.01-≤8%, 8.01-≤15%, and >15% 
(i.e., the tract with the highest percentage of people living below the poverty level).
 We also obtained clinical characteristics from SEER, including cancer site 
(colon or rectum), AJCC stage (II or III), histologic grade (well/moderately 
differentiated, poorly/undifferentiated, or unknown), tumor size (<2cm, 2-<3cm, 3-
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<4cm, ≥4cm, or unknown), and number of lymph nodes examined (<12 nodes, ≥12 
nodes, or unknown). The Charlson Comorbidity Index was measured from the 365 
days of Medicare inpatient and outpatient claims prior to diagnosis using the 
methodology developed by Klabunde et al.77  
Hospital characteristics 
 We retrieved characteristics of hospitals where patients received colorectal 
cancer surgery from the SEER-Medicare Hospital file. Hospital characteristics 
included NCI center designation (none, clinical, or comprehensive), NCI cooperative 
membership group count (0 or ≥1), teaching hospital status (yes or no), type of 
hospital (non-profit, private, or government), and total bed size, measured in 
quartiles (<204 beds, 204-343 beds, 344-487 beds, or 488+ beds).  
Physician characteristics 
 We obtained characteristics of physicians who treated patients with 
chemotherapy from the AMA Physician Masterfile and included medical degree 
(Medical Doctor (MD) or Doctor of Osteopathy (DO)), whether the physician was 
trained in the US (yes or no), year of medical school graduation (<1981 or ≥1981), 
primary specialty (oncology, hematology/oncology, hematology, internal medicine, or 
other), and sex.   
Measurement of specific chemotherapeutic agents for the treatment of CRC 
We categorized patients as receiving any chemotherapy treatment using 
International Classification of Disease, 9th Revision, Clinical Modification (ICD-9-CM) 
diagnosis, ICD-9-CM procedure, Current Procedural Terminology (CPT), and 
Healthcare Common Procedure Coding System (HCPCS), and revenue center 
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codes. Because we were concerned with identifying initial treatment with 5-FU, 
capecitabine, oxaliplatin, irinotecan, and bevacizumab, specifically, we excluded 
patients with administration codes only, as we were unable to identify the agents 
they received. Initial treatment with these agents was defined using the two month 
period of claims data following the first chemotherapy claim for each patient. The 
administrative codes used to identify any chemotherapy, the specific agents, and 
their measures of validity using previously published methods49,93 are listed in the 
Appendix C.  
Statistical analysis 
 We estimated the prevalence (and its 95% confidence interval (CI) of 1) any 
chemotherapy use among all eligible stage II and III CRC patients and 2) specific 
agents among all patients treated with chemotherapy (and having at least one 
specific agent claim) by year, cancer site, and stage. All analyses were performed 
on the chemotherapeutic agent-level so that individuals could be counted more than 
once in a given year (e.g., if they received both oxaliplatin and 5-FU). Therefore, the 
percentages do not sum to 100%. We present results for specific agents with ≥5% 
prevalence in at least one year. Logistic regression models stratified by cancer site 
and year were used to test for trends in the utilization of any chemotherapy from 
2000-2007 and for specific agents from 2004-2007. All models included patient age 
in 5-year categories (66-69, 70-74, 75-79, 80-84, 85+) to control for changes to the 
US population age structure over time, and diagnosis year to assess time trends. 
Trends in the replacement of 5-FU with capecitabine were estimated by 
measuring the proportion of capecitabine use among all users of fluoropyrimidines 
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by year, cancer site, and stage. Individuals receiving both 5-FU and capecitabine in 
the 2-months following their first chemotherapy claims were excluded from the 
analysis (n=83). Because the administrative definition for identifying capecitabine in 
Medicare claims has a very low sensitivity (47%), but high specificity (98%), we 
sought to estimate the proportion of patients receiving capecitabine that were 
missed by Medicare claims. The following equation was used to calculate the 
additional number of patients receiving capecitabine: 
Ncap_corr =(Ncap-(1-Secap)*(Nyr_tot- N5fu_tot)/(Secap+Spcap-1)94  
Where Ncap_corr is the number of capecitabine users, corrected for the 
misclassification in Medicare claims, Ncap is the number of capecitabine users 
identified by Medicare claims, Nyr_tot is the total number of individuals in site/stage 
patient group, N5fu_tot is the total number of 5-FU users in site/stage patient group, 
and Secap and Spcap are the sensitivity and specificity of the administrative definitions 
used to identify capecitabine in Medicare claims.     
 These additional patients were added to the total number of 5-FU and 
capecitabine users and the proportion of patients receiving 5-FU, capecitabine (as 
measured by claims), and capecitabine (as imputed using validation data) were 
graphed.     
 We estimated the proportion of patients receiving any chemotherapy and 
oxaliplatin, specifically, across patient demographic and clinical variables and 
calculated univariate prevalence ratios for the receipt of oxaliplatin for each patient, 
physician, and hospital characteristic.  
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Patient observations for the oxaliplatin cohort were clustered within hospitals 
and physicians in a non-nested manner. Miglioretti and Heagerty have developed a 
generalized estimating equation (GEE) strategy that can be used to adjust for the 
correlation among observations within non-nested multi-level data and provide 
estimates of marginal (population-averaged) associations.95 We used this strategy to 
account for the correlations of oxaliplatin receipt among patients who were treated 
with chemotherapy by the same physician and/or underwent surgery at the same 
hospital. The patient was the unit of analysis and the hospital’s provider number and 
the physician’s UPIN were the clustering variables. We estimated prevalence ratios 
for patient, physician and hospital variables using multivariate Poisson models with a 
log link and an independent GEE working matrix. Separate analyses for on- and off-
label indications were performed, as the influence of the selected characteristics 
may vary by indication. Finally, we assessed the contribution of the measured 
patient, physician, and hospital characteristics on the explained variation in the 
receipt of oxaliplatin by calculating and comparing the c-statistic for four models, 
including: 1) all patient, physician and hospital variables, 2) patient-level variables 
only, 3) physician-level variables only, and 4) hospital-level variables only. All 
statistical analyses were conducted using the SAS Version 9.2 (SAS Institute, Inc., 
Cary, NC).  
 
 
C.  RESULTS  
Specific agent trends cohort 
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 We identified 32,287 patients diagnosed with stage II or III colorectal cancer 
who met all SEER and Medicare eligibility criteria. The left columns of Table 5.1 
report the demographic and clinical characteristics of this cohort. Percentages are 
calculated across rows to reflect the proportion of the specified group receiving 
chemotherapy. Overall, 41% of patients received chemotherapy.  
The prevalence of chemotherapy receipt among this cohort is illustrated in 
Figure 5.1 by year, cancer site, and stage. Treatment with any chemotherapy was 
highest among stage III rectal and colon cancer patients. The utilization of 
chemotherapy in stage II rectal cancer increased over the time period (p=0.006) 
while utilization in stage II colon cancer decreased (p<0.0001).  
 Among those receiving chemotherapy, we identified 12,839 patients who had 
at least one Medicare claim for a specific chemotherapeutic agent. Our analysis of 
the prevalence of specific agents and their associated 95% CIs was limited to this 
group and is pictured by year, cancer site and stage in Figure 5.2a-d, noting the 
number of individuals included in the analysis for each year. For all cancer site and 
stage combinations, the utilization of 5-FU significantly decreased from 2000-2007 
across all cancer sites and stages (p<0.0001), with prevalence close to 100% for all 
site and stage combinations in 2000 and dropping to around 70% by 2007. 
Accordingly, Capecitabine utilization increased from 2004-2007 in all groups (p< 
0.0001), but was most noticeable in patients diagnosed with stage II rectal cancer 
with a prevalence of 38% in 2007. The utilization of oxaliplatin increased 
substantially from 2004-2007 (stage II colon: p<0.0001; stage III colon: p< 0.001; 
stage II rectum: p=0.006; stage III rectum: p=0.0003) and was highest among 
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patients diagnosed with stage II and III colon cancers. Bevacizumab use was 
minimal in stage II and III colon cancer over the study period, but increased to a 
prevalence of almost 10% by 2007 (stage II colon: p=0.002; stage III colon: 
p<0.0001). Irinotecan was used in less than 10% of stage III colon and rectal cancer 
patients during the entire time period. Use of irinotecan in stage III colon cancer 
decreased slightly from 2004-2007 (p=0.05), but the same was not true for stage III 
rectal cancer (p=0.99).  
 Trends in the replacement of 5-FU with capecitabine are illustrated in Figure 
5.3a-d. Relying upon Medicare claims alone may understate the use of capecitabine. 
Therefore, we estimated the additional proportion of patients using capecitabine that 
were missed by claims relying upon the previous validation study methods93 starting 
in 2005, the year that capecitabine was approved for use in stage III colon cancer. 
The share of individuals using capecitabine steadily increased after 2005 and is 
most pronounced in the stage II colon and rectal cancer groups, likely due to more 
frequent substitution in the single-agent setting. By 2007, almost 70% of all 
individuals treated with chemotherapy in the stage II rectal cancer group were 
treated with capecitabine, after accounting for misclassification. 
Oxaliplatin cohort  
 We identified 4,819 patients diagnosed with stage II or III colorectal cancer 
who met all SEER, Medicare, surgery, and chemotherapy eligibility criteria for 
inclusion in the analysis examining the influence of patient, physician, and hospital 
characteristics on the receipt of oxaliplatin. The right columns of Table 5.1 report the 
demographic and clinical characteristics of this cohort.  
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 Table 5.2 summarizes the characteristics of the physicians (n=1,579) and 
hospitals (n=795) included in the oxaliplatin analysis and the number and 
percentage of patients receiving oxaliplatin for each group. The majority of 
physicians were male (82%), MDs (97%), US-trained (67%), medical school 
graduates ≥1981 (56%) and had a primary specialty of oncology or 
hematology/oncology (76%). Most hospitals in the analysis were lacking NCI cancer 
center designation (97%) and cooperative group memberships (51%). About 40% 
were teaching hospitals and over 60% were non-profit entities. In univariate 
analyses, patients who were treated by MDs and US-trained physicians were more 
likely to receive oxaliplatin. Patients undergoing CRC surgery at non-profit and 
teaching hospitals were less likely to receive oxaliplatin treatment.   
 Overall, 2,183 patients (52%) received oxaliplatin as part of the initial course 
of treatment, reflecting a prevalence of on- and off-label treatment of 56% and 29%, 
respectively. Table 5.3 reports the unadjusted overall, adjusted overall, and on- and 
off-label adjusted prevalence ratios (PRs) for the receipt of oxaliplatin across patient, 
physician, and hospital characteristics. In the overall adjusted analysis, older age 
(e.g., 85+ vs. 66-69: aPR =0.24, 95% CI: (0.12, 0.48)), other marital status 
(separated, divorced, or widowed vs. married: aPR =0.89, 95% CI: (0.78, 1.01)), and 
earlier year of diagnosis (e.g., 2004 vs. 2007: aPR =0.42, 95% CI: (0.31, 0.51)) were 
associated with a lower prevalence of oxaliplatin treatment. Patients diagnosed with 
colon vs. rectal cancer were more likely to receive oxaliplatin (aPR=2.28, 95% CI: 
(1.74, 2.98)), whereas those diagnosed with stage II vs. III disease were less likely 
(aPR= 0.65, 95% CI: (0.56, 0.76)). There were (statistically non-significant) trends in 
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the associations between higher Charlson comorbidity scores (e.g., 2+ vs. 0: 
aPR=0.88, 95% CI: (0.71, 1.08)) and higher percentage of the census tract living 
under the poverty level (e.g., 4th vs. 1st: aPR=0.91, 95% CI: (0.77, 1.09)), and a 
lower prevalence of oxaliplatin treatment.    
 In general, the influences of patient, physician, and hospital characteristics on 
the receipt of oxaliplatin in the on- and off-label settings were similar to the overall 
cohort. In the off-label analysis patients diagnosed with stage II rectal cancer were 
substantially less likely to receive oxaliplatin than those diagnosed with stage II 
colon cancer (aPR=0.39, 95% CI: (0.28, 0.54)).     
 The overall Poisson model including all patient, physician, and hospital 
variables had a c-statistic (or area under the receiver operating curve) of 77.6%. 
Patient-level characteristics accounted for almost all of the explained variation (c-
statistic=77.5%), while physician-level and hospital-level characteristics did not 
explain receipt of oxaliplatin (c-statistic=53.1% and 53.5%, respectively). Thus, after 
conditioning upon the receipt of any chemotherapy, the explainable variation in the 
receipt of oxaliplatin appears to be almost exclusively driven by patient-level factors.      
 
 
D.  DISCUSSION 
 In this population-based analysis among patients who received chemotherapy 
treatment, there were substantial shifts in the utilization of specific chemotherapeutic 
agents used to treat stage II and III CRC patients diagnosed from 2000–2007. For all 
cancer site and stage combinations, the utilization of capecitabine and oxaliplatin 
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increased substantially from 2004-2007, while 5-FU decreased. Use of bevacizumab 
in stage II and III colon cancer significantly increased, while irinotecan use remained 
relatively constant among stage III CRC patients, likely because data on its lack of 
efficacy were not reported until 2007.25,26 After receiving FDA approval for stage III 
colon cancer in 2005, the proportion of patients treated with capecitabine (in place of 
5-FU) increased over time, particularly in stage II CRC where single agent use is 
common.   
 Measured patient-level characteristics appeared to drive most of the 
explainable variation in receipt of oxaliplatin among individuals diagnosed with stage 
II or III CRC between 2004 and 2007. In particular, patients who were younger, 
female, married, and diagnosed in later study years were more likely to receive 
oxaliplatin. Those patients diagnosed with cancer of the colon, stage III disease, and 
having no comorbidities (measured by the Charlson comorbidity score) were also 
more likely to receive oxaliplatin. In multivariate analyses, DOs and physicians 
trained outside of the US were less likely to treat patients with oxaliplatin; however, 
these associations were not statistically significant. The primary specialty of the 
physician treating the patient did not appear to influence the prevalence of treatment 
with oxaliplatin. In general, the characteristics of hospitals where patients received 
their CRC surgery did not have a strong influence on a patient’s receipt of oxaliplatin 
after adjustment for other factors and clustering.  
 Few studies have examined trends in treatment with specific 
chemotherapeutic agents over time among stage II and III CRC patients. Ferro and 
colleagues57 conducted a cross-sectional study of 115 ambulatory centers in the US 
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to examine the utilization of 8 of the most commonly prescribed chemotherapeutic 
regimens by 421 individuals diagnosed with primarily metastatic CRC (mCRC) 
between 2002 and 2005. In line with our results, utilization of oxaliplatin substantially 
increased after FDA approval for mCRC, late in 2004 while 5-FU decreased. A more 
recent study by Hsiao et al58 drew upon the SEER-Medicare database and reported 
the utilization of three regimens, 5-FU/LV alone, irinotecan-based regimens, and 
oxaliplatin-based regimens for stage III colon cancer patients by year of diagnosis 
from 2002-2005. Similar levels of utilization were reported for oxaliplatin of 
approximately 35% in 2004 and 57% in 2005.    
A number of studies have examined associations between patient and 
physician characteristics and the receipt of any chemotherapy among stage II and III 
CRC patients. In general, age, sex, race/ethnicity, region, area-level SES, cancer 
site, nodal status, and number of comorbidities have been shown to influence the 
receipt of initial chemotherapy treatment.55,61,64,66,70,72 Physician characteristics, such 
as younger age and receipt of US-based training, have also been shown to predict 
the receipt of chemotherapy overall.71  
However, our study focused on a population of stage II and III CRC patients 
receiving chemotherapy and attempted to distinguish the patient, physician, and 
hospital characteristics associated with the receipt of oxaliplatin, specifically. After 
conditioning upon chemotherapy receipt, the influence of access to care-related 
variables appeared to diminish. The associations between race/ethnicity and 
metropolitan county area status and oxaliplatin receipt are no longer seen. Hsiao58 
and Kahn70 reported that among patients receiving chemotherapy, elderly patients 
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and those with more comorbidity were less likely to receive oxaliplatin treatment, 
which are consistent with the results of our study. The apparent age barrier to the 
receipt of oxaliplatin is in stark contrast to the evidence about lack of differences in 
the efficacy,73 effectiveness,124 and safety70 of oxaliplatin in older stage III colon 
cancer patients.     
A study by Becker et al79 examined patient and physician predictors of 
oxaliplatin use in stage III colon cancer patients diagnosed from September 2004-
December 2005. The authors found that without conditioning on chemotherapy 
receipt, younger age, white race, being married, having fewer comorbidities, urban 
location, having a poorly/undifferentiated tumor, and having a younger physician 
were associated with increased odds of oxaliplatin receipt. A recent study by Abrams 
et al59 performed a cross-sectional study using an outpatient chemotherapy ordering 
system in the US. This study identified patients receiving adjuvant chemotherapy 
between 2004 and the beginning of 2010. In 2004, 39% of stage III colon cancer 
patients received oxaliplatin with a fluoropyrimidine, but by 2007, this percentage 
increased to 90%. Stage II colon cancer patients also experienced a rapid increase 
in oxaliplatin use, reaching 79% by 2008. Older age was again associated with 
decreased receipt of oxaliplatin in both stage II and III colon cancer patients. Our 
study expands upon these findings by 1) including stage II and III rectal cancer 
patients, 2) seeking to estimate trends in replacement of 5-FU with capecitabine, 
and 3) augmenting our predictive analysis with additional data (i.e., hospital-level 
characteristics).        
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This study has multiple strengths. First, the data are derived from population-
based cancer registry and healthcare utilization resources, providing a “real world” 
context for studying patterns of chemotherapy use in the community setting. In 
addition, this is one of the first studies to examine the extent of on- and off-label use 
of a number of specific chemotherapeutic agents in routine practice over time. 
Lastly, through further linkages to the AMA Masterfile and SEER-Medicare hospital 
file, we were able to construct a rich multilevel data source to examine the influence 
of patient, physician, and hospital characteristics on the receipt of oxaliplatin.  
Our study is not without limitations, however. The SEER-Medicare data 
provide information on many important patient and tumor characteristics that may be 
associated with treatment patterns, but unobserved factors such as patient 
preference or comorbidities not assessed through the Charlson Comorbidity Index 
may also influence treatment receipt. The physician and hospital data were 
somewhat limited; therefore other unmeasured physician and hospital factors may 
help to explain the variation in oxaliplatin treatment. Additionally, cohort entry was 
restricted by multiple criteria in order to ensure full healthcare utilization, treatment 
capture, and linkage to the two additional data sources. These criteria included 
having continuous Medicare Parts A and B enrollment (with no HMO enrollment), a 
claim for CRC surgery within 6-months from diagnosis at a hospital matched to the 
Hospital file, and a claim for a specific chemotherapeutic agent within 8-months of 
diagnosis, which may reduce the generalizability of our findings.  
In conclusion, the utilization of capecitabine and oxaliplatin has increased 
markedly among stage II and III CRC patients receiving chemotherapy from 2004-
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2007. After conditioning on the receipt of chemotherapy, 52% of all stage II and III 
CRC patients received oxaliplatin from 2004-2007. Much of this use was attributable 
to patients with off-label indications, for which RCT evidence is lacking or has shown 
little to no benefit. Patient characteristics appeared to drive most of the explainable 
variation in the receipt of oxaliplatin for both on- or off-label use. Off-label use of 
specific chemotherapeutic agents in stage II and III CRC is relatively common in 
routine practice; however, clinicians deciding to treat patient off-label should 
carefully weigh the unknown or minimal benefits of treatment against potentially 
serious side effects.    
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Patient characteristics
n=18,951 % n=13,336 % n=2,636 % n=2,183 %
Demographic characteristics
Gender
  Male 7,555      55 6,259      45 1,289  56 1010 44
  Female 11,396    62 7,077      38 1,347  53 1173 47
Age at diagnosis (mean, SD)
  65 - 69 1,784      36 3,200      64 598     46 697 54
  70 - 74 3,075      43 4,056      57 753     51 713 49
  75 - 79 4,174      54 3,535      46 716     56 553 44
  80 - 84 4,880      71 1,955      29 434     69 199 31
  85+ 5,038      90 590         10 135     87 21 13
Race
   White Non-Hispanic 15,712    59 10,822    41 2,132  55 1766 45
   Black Non-Hispanic 1,408      61 891         39 159     54 135 46
   Hispanic 885         52 803         48 176     57 135 43
   Other Non-Hispanic 898         53 796         47 166     54 142 46
   Unknown 48           67 24           33 3         38 5 63
Marital status
  Married 8,071      51 7,739      49 1,514  52 1,387  48
  Single 1,586      63 925         37 173     54 148     46
  Other 8,476      67 4,185      33 868     60 570     40
  Unknown 818         63 487         37 81       51 78       49
County of residence in metro areas size
    Metropolitan 15,709    58 11,173    42 2,188  54 1,871  46
    Non-metropolitan 3,240      60 2,163      40 448     59 312     41
    Missing 2            100 -         0 -      0 -      0
Percentage living below poverty level‡
  ≤ 4% 4,090      57 3,076      43 591     51 561     49
  4-8% 5,189      58 3,736      42 718     53 644     47
  8-15% 4,742      60 3,212      40 653     57 490     43
  >15% 4,930      60 3,312      40 674     58 488     42
Year of diagnosis
  2000 2,302      57 1,712      43 na - na -
  2001 2,430      58 1,730      42 na - na -
  2002 2,386      57 1,774      43 na - na -
  2003 2,420      57 1,839      43 na - na -
  2004 2,528      61 1,640      39 1,026  75 341     25
  2005 2,409      59 1,670      41 718     56 554     44
  2006 2,307      61 1,448      39 487     44 621     56
  2007 2,169      59 1,523      41 405     38 667     62
Region
  Northeast 4,741      59 3,301      41 671     58 489     42
  South 3,437      57 2,547      43 533     57 409     43
  Midwest 2,998      59 2,107      41 458     60 301     40
  West 7,775      59 5,381      41 974     50 984     50
Table 5.1. Characteristics of elderly stage II or III colorectal cancer patients by cohort and treatment*
2000-2007 cohort 2004-2007 cohort†
No chemo Chemo
Chemo 
without 
oxaliplatin
Chemo 
with 
oxaliplatin
79.7 (7.1) 74.3 (5.6) 74.7 (5.7) 72.8 (4.8)
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Tumor characteristics at diagnosis
Cancer site
  Colon 17,344    62 10,765    38 1,959  49 2,023  51
  Rectum 1,607      38 2,571      62 677     81 160     19
AJCC/Derived AJCC stage
  II 13,534    76 4,266      24 930     69 419     31
  III 5,417      37 9,070      63 1,706  49 1,764  51
Histologic grade
  Well/moderately-differentiated 14,582    61 9,520      39 1,887  56 1,511  44
  Poorly/undifferentiated 3,855      54 3,315      46 644     51 616     49
  Unknown 514         51 501         49 105     65 56       35
Tumor size
  <2 cm 600         51 569         49 153 60 104 40
  2-<3 cm 1,935      59 1,348      41 270 51 259 49
  3-<4 cm 3,423      59 2,337      41 472 54 397 46
  ≥4 cm 11,712    60 7,716      40 1488 54 1266 46
  Unknown 1,281      48 1,366      52 253 62 157 38
Number of lymph nodes examined
  <12 nodes 8,613      58 6,172      42 1106 62 688 38
  >12 nodes 10,063    59 6,927      41 1495 51 1464 49
  Unknown or nodes not examined 275         54 237         46 35 53 31 47
Charlson Comorbidity Index
  0 11,957    56 9,247      44 1717 53 1507 47
  1 4,477      61 2,904      39 655 57 492 43
  2+ 2,517      68 1,185      32 264 59 184 41
‡ Percentage of census tract living below the poverty line and county of residence in metro area size are linked 
from 2000 Census data.
* Cases obtained from the SEER 17 registries were included in this analysis.
† The 2004-2007 cohort includes 4,219 individuals who received chemotherapy treatment (with a specific agent 
claim), had surgery performed at a hospital identified in the Hospital file, and were treated with chemotherapy 
by a physician included in the AMA Physician Masterfile. 
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Characteristic
N % N %
Physician characteristics (n=1,579)
Degree
  MD 1,526          96.6 2,118         45.7
  DO 53               3.4 65              36.1
US-Trained
  Yes 1,054          66.8 1,464         46.4
  No 525             33.2 719            43.2
Medical School Graduation
  <1981 697             44.1 995            44.3
  ≥1981 882             55.9 1,188         46.1
Primary specialty
  Oncology 710             45.0 1,079         45.9
  Hematology/Oncology 484             30.7 635            44.4
  Hematology 484             30.7 237            46.7
  Internal Medicine 139             8.8 180            43.5
  Other specialty 78               4.9 52              44.4
Gender
  Male 1,289          81.6 1,882         45.5
  Female 290             18.4 301            44.3
Hospital characteristics (n=795)*
NCI center designation
  None 849             97.1 2,113         45.3
  Clinical 4                 0.5 9               50.0
  Comprehensive 21               2.4 61              43.6
NCI cooperative group membership count 
  None 447             51.1 696            44.9
  1+ 427             48.9 1,487         45.5
Teaching hospital
  Yes 346             39.6 1,087         43.1
  No 521             59.6 1,093         47.7
  Unknown 7                 0.8 3               33.3
Type of hospital
  Non-profit 543             62.1 1,661         44.4
  Private 166             19.0 262            48.6
  Government 158             18.1 257            48.5
  Unknown 7                 0.8 3               33.3
Total bed size
  < 204 beds 402             46.0 558            46.5
  204 - 343 beds 209             23.9 549            45.6
   344 - 487 beds 143             16.4 564            47.0
  488+ beds 120             13.7 512            42.2
NCI=National Cancer Institute
Table 5.2. Characteristics of the physician and hospitals providing care for elderly 
stage II and III colorectal cancer patients who were diagnosed from 2004-2007 and 
received treatment with specific chemotherapy agents
Physicians/ 
hospitals included 
in analysis
Patients 
receiving 
chemotherapy 
with oxaliplatin
*All hospital information was obtained from the year of patient diagnosis with exception of 
the NCI cancer center designation and cooperative group count which are reported for the 
year 2002. The total number of hospitals repored here (n=874) is greater than the total 
number of unique hospitals because some of the hospital characteristics changed over time 
and are reported here according to year of the patient's cancer diagnosis.
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Overall Overall On-Label Off-Label
Unadjusted Adjusted* Adjusted* Adjusted*
Characteristics PR (95% CI) PR (95% CI) PR (95% CI) PR (95% CI)
N 4,219 4,219 2,939 1,880
% receiving oxaliplatin 51.74 51.74 55.84 28.83
Demographic characteristics
Gender
  Male 1.00 1.00 1.00 1.00
  Female 1.06 (1, 1.13) 1.07 (0.95, 1.19) 1.03 (0.91,  1.16) 1.17 (0.9,  1.53)
Age category
  65 - 69 1.00 1.00 1.00 1.00
  70 - 74 1.11 (1.04, 1.18) 0.91 (0.81, 1.03) 0.88 (0.77, 1) 0.97 (0.73, 1.28)
  75 - 79 0.95 (0.88, 1.02) 0.76 (0.67, 0.88) 0.76 (0.66, 0.88) 0.72 (0.51, 1.02)
  80 - 84 0.66 (0.59, 0.75) 0.55 (0.43, 0.7) 0.53 (0.41, 0.68) 0.6 (0.36, 1.02)
  85+ 0.29 (0.19, 0.43) 0.24 (0.12, 0.48) 0.25 (0.12, 0.52) 0.22 (0.03, 1.44)
Race/ethnicity
  White Non-Hispanic 1.00 1.00 1.00 1.00
  Black Non-Hispanic 1.02 (0.89, 1.15) 1.05 (0.83, 1.32) 1.07 (0.84, 1.36) 0.96 (0.52, 1.78)
  Other Non-Hispanic 1.02 (0.9, 1.16) 0.94 (0.71, 1.25) 0.9 (0.69, 1.19) 1.04 (0.61,1.8)
  Hispanic 0.96 (0.84, 1.09) 0.97 (0.77, 1.21) 0.98 (0.78, 1.25) 0.95 (0.57, 1.58)
Marital status
  Married 1.00 1.00 1.00 1.00
  Single 1.02 (0.9, 1.16) 0.94 (0.76, 1.16) 0.95 (0.75, 1.19) 0.83 (0.51, 1.36)
  Other (separated, widowed, divorced) 0.83 (0.77, 0.9) 0.89 (0.78, 1.01) 0.88 (0.76, 1) 0.89 (0.67, 1.19)
County of residence in metro areas size
    Metropolitan 1.12 (1.02, 1.23) 1.13 (0.93, 1.37) 1.12 (0.92, 1.37) 1.12 (0.74, 1.71)
    Non-metropolitan 1.00 1.00 1.00 1.00
Percent living below poverty level†
  ≤ 4% 1.00 1.00 1.00 1.00
  4-8% 1.06 (0.99, 1.14) 0.99 (0.87, 1.13) 1 (0.86, 1.15) 0.98 (0.72, 1.33)
  8-15% 0.93 (0.86, 1) 0.93 (0.79, 1.09) 0.91 (0.76, 1.07) 1 (0.71, 1.41)
  >15% 0.91 (0.84, 0.98) 0.91 (0.77, 1.09) 0.94 (0.79, 1.13) 0.84 (0.56, 1.27)
Year of diagnosis
  2004 0.47 (0.42, 0.52) 0.42 (0.34, 0.51) 0.47 (0.38, 0.58) 0.29 (0.18, 0.45)
  2005 0.95 (0.88, 1.02) 0.73 (0.64, 0.84) 0.8 (0.69, 0.92) 0.84 (0.54, 1.29)
  2006 1.33 (1.25, 1.42) 0.95 (0.84, 1.08) 0.98 (0.86,1.11) 0.88 (0.57, 1.36)
  2007 1.00 1.00 1.00 1.00
Region
  East 0.91 (0.84, 0.98) 0.86 (0.7, 1.05) 0.87 (0.71, 1.05) 0.84 (0.54, 1.29)
  South 0.95 (0.88, 1.03) 0.9 (0.74, 1.1) 0.91 (0.75, 1.09) 0.88 (0.57, 1.36)
  Midwest 0.86 (0.78, 0.94) 0.87 (0.68, 1.11) 0.88 (0.69, 1.12) 0.84 (0.53, 1.33)
  West 1.00 1.00 1.00 1.00
Table 5.3. Unadjusted and adjusted prevalence ratio estimates for the associations between patient, physician, 
and hospital characteristics and the receipt of oxaliplatin
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Tumor characteristics at diagnosis
Cancer site
  Colon 2.66 (2.3, 3.07) 2.28 (1.74, 2.98) - -
  Rectum 1.00 1.00 - -
AJCC/Derived AJCC stage
  II 0.61 (0.56, 0.67) 0.65 (0.56, 0.76) - -
  III 1.00 1.00 - -
Cancer site and stage combination (off-label)
  Stage II Colon - - - 1.00
  Stage II Rectum - 0.39 (0.28, 0.54)
  Stage III Rectum - - - 0.69 (0.38, 1.28)
Histologic grade
  Well/moderately-differentiated 0.91 (0.85, 0.97) 0.96 (0.86, 1.08) 0.98 (0.87, 1.11) 0.93 (0.7, 1.23)
  Poorly/undifferentiated 1.00 1.00 1.00 1.00
Tumor size
  <2 cm 0.87 (0.75, 1.02) 0.92 (0.79, 1.07) 1 (0.77, 1.3) 0.7 (0.35, 1.41)
  2-<3 cm 1.08 (0.98, 1.18) 1.01 (0.88, 1.15) 0.99 (0.85, 1.17) 1.11 (0.76, 1.63)
  3-<4 cm 0.99 (0.92, 1.08) 0.96 (0.85, 1.08) 1 (0.87, 1.15) 0.83 (0.57, 1.21)
  ≥4 cm 1.00 1.00 1.00 1.00
Number of lymph nodes examined
  <12 nodes 1.00 1.00 1.00 1.00
  >12 nodes 1.29 (1.2, 1.38) 1.08 (0.84, 1.39) 1.12 (0.98, 1.27) 0.98 (0.76, 1.28)
Charlson comorbidity score
  0 1.00 1.00 1.00 1.00
  1 0.93 (0.86, 1) 0.92 (0.81, 1.04) 0.91 (0.8, 1.04) 0.95 (0.7, 1.28)
  2+ 0.9 (0.8, 1.01) 0.88 (0.71, 1.08) 0.81 (0.64, 1.04) 0.99 (0.67, 1.48)
Physician characteristics
Degree
  MD 1.00 1.00 1.00 1.00
  DO 0.79 (0.65, 0.96) 0.82 (0.52, 1.28) 0.83 (0.52, 1.32) 0.79 (0.33, 1.91)
US-Trained
  Yes 1.00 1.00 1.00 1.00
  No 0.93 (0.87, 1) 0.94 (0.81, 1.09) 0.95 (0.83, 1.1) 0.93 (0.68, 1.28)
Medical School Graduation
  <1981 1.00 1.00 1.00 1.00
  ≥1981 1.04 (0.98, 1.11) 0.96 (0.84, 1.11) 0.99 (0.86, 1.14) 0.87 (0.66, 1.15)
Gender
  Male 1.00 1.00 1.00 1.00
  Female 0.98 (0.89, 1.07) 0.99 (0.83, 1.19) 0.98 (0.82, 1.19) 1.03 (0.7, 1.52)
Specialty
  Oncology 1.00 1.00 1.00 1.00
  Hematology/Oncology 0.97 (0.91, 1.04) 1.04 (0.88, 1.23) 1.03 (0.87, 1.22) 0.98 (0.7, 1.38)
  Hematology 1.03 (0.94, 1.14) 1.02 (0.84, 1.23) 1.04 (0.85, 1.28) 1 (0.63, 1.57)
  Internal Medicine 0.96 (0.85, 1.07) 1.02 (0.81, 1.27) 1.02 (0.83, 1.26) 0.99 (0.58, 1.7)
  Other 0.98 (0.8, 1.2) 1.06 (0.7, 1.59) 0.94 (0.59, 1.51) 1.21 (0.65, 2.26)
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Hospital characteristics
NCI center designation‡
  None 1.00 1.00 1.00 1.00
  Clinical 1.1 (0.7, 1.75) 1.16 (0.65, 2.04) 1.12 (0.63, 1.97) 1.22 (0.31, 4.71)
  Comprehensive 0.96 (0.79, 1.16) 1.08 (0.75, 1.56) 1.21 (0.85, 1.71) 0.79 (0.31, 1.98)
NCI cooperative group membership count‡
  None 1.00 1.00 1.00 1.00
  1+ 1.01 (0.95, 1.08) 1.01 (0.85, 1.19) 0.97 (0.83, 1.14) 1.12 (0.79, 1.58)
Teaching hospital
  Yes 0.9 (0.85, 0.96) 0.95 (0.81, 1.12) 0.94 (0.8, 1.1) 0.99 (0.7, 1.4)
  No 1.00 1.00 1.00 1.00
Type of hospital
  Non-profit 1.00 1.00 1.00 1.00
  Private 1.08 (0.99, 1.19) 0.98 (0.81, 1.19) 1.03 (0.85, 1.24) 0.86 (0.53, 1.4)
  Government 1.08 (0.98, 1.19) 1.05 (0.87, 1.27) 1.07 (0.88, 1.29) 0.98 (0.64, 1.5)
Total bed size
  < 204 beds 1.00 1.00 1.00 1.00
  204 - 343 beds 1.01 (0.94, 1.08) 0.99 (0.83, 1.19) 1.06 (0.88, 1.28) 0.81 (0.56, 1.17)
   344 - 487 beds 1.05 (0.98, 1.13) 0.99 (0.81, 1.21) 1.04 (0.85, 1.28) 0.83 (0.56, 1.22)
  488+ beds 0.91 (0.84, 0.98) 0.95 (0.74, 1.22) 0.98 (0.76, 1.26) 0.85 (0.54, 1.33)
‡ NCI cancer center designation and cooperative group count were reported as of the year 2002.
* Models are adjusted for all other covariates listed. Generalized estimating equations for non-nested clusters were utilized to estimate 
appropriate standard errors. 
† Percentage of census tract living below the poverty line and county of residence in metro area size are linked from 2000 Census 
data.
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Figure 5.1. Prevalence of the receipt of any chemotherapy by cancer site, stage, and year of 
diagnosis, 2000-2007.  
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a) Stage II Colon Cancer 
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b) Stage III Colon Cancer  
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c) Stage II Rectal Cancer 
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d) Stage III Rectal Cancer 
 
 
Figure 2a-d. Prevalence of treatment with specific chemotherapeutic agents by cancer site and 
stage, 2000-2007. Panels a, b, c, and d refer to stage II colon, stage III colon, stage II rectal, and 
stage III rectal cancers, respectively. Individuals could be counted multiple times if they received 
more than one agent within the two-months after the first chemotherapy claim (e.g., a patient 
receiving oxaliplatin and 5-FU).The total number of individuals included in the analysis is reported 
below the year of diagnosis. We included specific agents that had a prevalence of ≥5% in at least one 
year. Error bars represent exact binomial 95% confidence intervals.  
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a) Stage II Colon Cancer b) Stage III Colon Cancer 
 
c) Stage II Rectal Cancer d) Stage III Rectal Cancer 
 
Figure 3a-d. Changes in the proportion of stage II and III colorectal cancer patients using capecitabine among all fluoropyrimidine users 
from 2000-2007 (n=12,540). The proportions in black represent 5-FU use and the proportions in light grey represent capecitabine use, as 
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measured directly from Medicare claims. The proportions in medium grey estimate capecitabine use that was missed based on a validation study 
by Lund et al and the calculation, Ncap_corr =(Ncap-(1-Secap)*(Nyr_tot- N5fu_tot)/(Secap+Spcap-1), where Ncap_corr  is the number of capecitabine users, 
corrected for the misclassification in Medicare claims, Ncap is the number of capecitabine users identified by Medicare claims, Nyr_tot is the total 
number of individuals in site/stage patient group, N5fu_tot is the total number of 5-FU users in site/stage patient group, and Secap and Spcap are the 
sensitivity and specificity of the administrative definitions used to identify capecitabine in Medicare claims. Individuals were excluded if they 
received both 5-FU and capecitabine in the two months following their first chemotherapy claim (n=83). 
  
 
 
 
 
 
CHAPTER 6 
 
DISCUSSION 
 
A.  SUMMARY OF FINDINGS 
This dissertation examined patterns of chemotherapeutic treatment among 
elderly stage II and III CRC patients through the linkage of data from administrative 
sources, population-based registries, and publicly available records. The research 
had two main objectives: 1) to assess the utility of Medicare claims to capture the 
receipt of any chemotherapy and specific agents delivered to patients diagnosed at 
age ≥65 with stage II or III colorectal cancer (CRC), in situ or early stage breast, 
non-small cell lung cancer (NSCLC), or ovarian cancer using various post-diagnosis 
claims windows (Specific Aim 1) and 2) to estimate the prevalence of specific 
chemotherapeutic agent use from 2000-2007 (Specific Aim 2a) and identify 
independent patient, physician, and hospital characteristics associated with the 
receipt of oxaliplatin (Specific Aim 2b) among elderly stage II and III CRC patients 
who receive chemotherapy.  
To address the first objective, Medicare claims were compared to data from the 
POC studies (the gold standard) in order to estimate measures of agreement and 
validity for the receipt of chemotherapy and specific agents. Results showed that the 
receipt of chemotherapy and specific intravenous agents can be identified using 
Medicare claims, showing improvement from prior reports. Yet, variation in the 
validity of specific agents exists. Future studies should assess newly-approved 
   118 
agents, regimens, and the impact of coverage decisions for these agents under the 
Medicare Part D program. 
To address the second objective, the description of trends in the utilization of 
specific chemotherapeutic agents for the treatment of stage II and III CRC from 
2000-2007 and identification of patient, physician, and hospital characteristics 
associated with the receipt of oxaliplatin from 2004-2007. There were substantial 
shifts in the utilization of specific chemotherapeutic agents used to treat stage II and 
III CRC patients diagnosed from 2000–2007. For all cancer site and stage 
combinations, the utilization of capecitabine and oxaliplatin increased substantially 
from 2004-2007, while 5-FU decreased. Use of bevacizumab in stage II and III colon 
cancer significantly increased, while irinotecan use remained relatively constant. 
Measured patient-level characteristics appeared to drive most of the explainable 
variation in receipt of oxaliplatin among individuals diagnosed with stage II or III CRC 
between 2004 and 2007; however a large portion of the variation remained 
unexplained. In particular, patients who were younger, married, living in a 
metropolitan area or low poverty level census tract, and diagnosed in later study 
years were more likely to receive oxaliplatin. Those patients diagnosed with cancer 
of the colon, stage III disease, and having no were also more likely to receive 
oxaliplatin. These findings 1) add support to the current literature confirming the 
accuracy of Medicare claims in identifying more recently approved chemotherapeutic 
agents, 2) contribute to the small but growing literature regarding the high levels of 
on- and off-label use of chemotherapeutic agents among stage II and III CRC 
patients, and 3) suggest that patient-level factors appear to drive the variation in 
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oxaliplatin use, underscoring the importance of weighing the potential benefits and 
harms when considering oxaliplatin treatment, particularly in the off-label setting. 
The results from the first research aim had an important implication for the 
design and conduct of the second research aim; if any of the specific agents were 
measured with poor accuracy (either low Se or Sp), the measurement of specific 
agent utilization would be biased. The results of Specific Aim 1 confirmed that 
capecitabine required additional attention in Specific Aim 2 due to under-
ascertainment of true use.  
 
B.  PUBLIC HEALTH IMPLICATIONS 
The results of this dissertation research have several implications for public 
health and clinical practice.  First, the finding that Medicare claims can accurately 
identify the receipt of any chemotherapy and specific intravenous agents will provide 
support to analyses seeking to examine patterns and effectiveness of chemotherapy 
treatment in elderly cancer patients. Because the elderly are often underrepresented 
in RCTs, evaluation of these agents in the diverse community setting is important to 
detect potential safety issues and over- or under-use of effective treatments.   
Additionally, the utilization of many chemotherapeutic agents, including 
oxaliplatin, capecitabine, and bevacizumab, are increasing over time with a large 
proportion of the treated population receiving these agents off-label. These results 
will highlight the magnitude of off-label prescribing among stage II and III CRC 
patients and potentially catalyze further research efforts to examine the benefits and 
harms of treatment for non-approved indications.  
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Finally, patient-level factors were found to drive the majority of explainable 
variation in the receipt of oxaliplatin for elderly stage II and III CRC receiving 
chemotherapy. In addition, two physician factors were more weakly associated with 
oxaliplatin receipt. These factors, taken together, could serve as potential targets for 
interventions seeking to encourage evidence-based approaches and equitable 
dissemination of oxaliplatin treatment.    
Chemotherapy treatment with combined oxaliplatin and fluoropyrimidine 
treatment has been shown to decrease disease recurrence and overall survival in 
stage III colon cancer patients. The results of this dissertation suggest that Medicare 
claims data can be used to accurately identify oxaliplatin and other specific 
chemotherapeutic agents for research studies evaluating patterns of care, 
effectiveness and safety among subgroups commonly excluded from RCTs. Early 
analysis in the Medicare data show that a substantial proportion of stage II colon and 
stage II and III rectal cancer patients receiving chemotherapy are treated with 
oxaliplatin. Tracking outcomes for these patients should help clarify the real world 
benefits and harms associated with oxaliplatin treatment. 
 
C.  STRENGTHS 
Use of the linked SEER-Medicare and POC data (Specific Aim 1) 
Through cooperation with the NCI and SEER registries, we linked verified 
treatment data obtained through physician confirmation or unified medical record 
review to Medicare claims for a large number of individuals aged ≥65 years and 
diagnosed with one of four different cancers. The detailed POC data collection 
   121 
protocol allowed us to assess the validity of Medicare claims to identify specific 
agents that have not previously been validated. We examined and reported variation 
in measures of validity across different post-diagnosis periods, whereas prior studies 
primarily used one or two broad post-diagnosis time windows.49,51,53 
Population-based examination of on- and off-label patterns of care in the 
elderly (Specific Aim 2) 
Only one prior study has assessed on- and off-label use of specific 
chemotherapeutic treatments for colon cancer using an outpatient ordering system, 
which may not be entirely representative of the elderly US population. Other studies 
relying upon population-based resources (such as SEER-Medicare) have not 
examined the utilization and predictors of oxaliplatin receipt according to on- and off-
label indication. The data for this dissertation were derived from a linkage between 
population-based cancer registries and administrative data from Medicare, providing 
a real world, population-based context for studying patterns of chemotherapy use 
among the elderly in routine clinical practice. This is one of the first studies to 
examine the extent of on- and off-label use of a number of specific 
chemotherapeutic agents, specifically among stage II and III rectal cancer patients.    
Multi-level analysis of factors influencing oxaliplatin receipt (Specific Aim 2) 
Lastly, through further linkages to the AMA Masterfile and SEER-Medicare 
hospital file, we were able to construct a rich multilevel data source to examine the 
influence of patient, physician, and hospital characteristics on the receipt of 
oxaliplatin among stage II and III CRC patients. Prior studies have primarily focused 
on the influence of patient factors and the receipt of oxaliplatin; however, the 
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interplay of multiple stakeholders in the treatment delivery process should be 
examined. We utilized a statistical approach developed by Miglioretti and Heagerty95 
that accounted for the non-nested clustering of patient observations at the physician 
and hospital levels.   
 
D. LIMITATIONS  
Misclassified gold standard treatment in the POC studies 
The first aim of this dissertation relied upon gold standard treatment information 
obtained from the POC studies. However, it is possible that this information was 
measured with error (e.g., a physician incorrectly reported a specific agent received, 
treatments listed were for recurrence and not for initial chemotherapy treatment, 
etc.). Additionally, it is unlikely that Medicare would provide reimbursement for a 
treatment that was not actually administered (i.e., false-positive treatment reported 
by Medicare claims). Therefore, the validity of specific agent reporting in Medicare 
claims (and the receipt of chemotherapy overall) may be underestimated in our first 
aim. However, we conducted a sensitivity analysis using oxaliplatin as an example 
and found that despite the potential for POC treatment misclassification, the Se, Sp, 
and PPV only increased slightly.       
Poor or unknown Se and Sp of specific agents in Medicare claims 
The second aim of this dissertation examined the utilization of specific 
chemotherapeutic agents among stage II and III CRC patients over time. In our 
analysis, we included capecitabine, which from our first aim was shown to have 
consistently low Se estimates using the Medicare claims for all post-diagnosis 
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periods. In addition, we examined the use of two specific agents, irinotecan and 
bevacizumab, which were not included in the first validation aim due to the low 
number of individuals receiving these agents in the POC data. Therefore, it is 
uncertain how accurate the reporting of these agents are in the Medicare claims 
data. However, irinotecan and bevacizumab are both expensive chemotherapy 
treatments, ranging in cost for an 8-week course of close to $9,000 and $21,000, 
respectively.125 Because of this high cost, physicians would be likely to submit 
claims for this agent and Medicare would be careful in appropriately reimbursing for 
this treatment. Therefore, we believe that the Se and Sp of Medicare claims to 
identify these treatments would be relatively high.    
Trade-off between increased validity of treatment reporting and selection bias 
In aims 2 and 3 of this dissertation, we were faced with handling a trade-off 
between increasing the validity of Medicare claims to identify chemotherapy 
treatment and inducing a selection bias based on requiring individuals to have 
continuous Medicare enrollment for the 8-months following diagnosis. From specific 
aim 1, we found that using an 8-month claims window post-diagnosis generally 
maximized the Se and Sp for identifying specific chemotherapeutic agents in 
Medicare claims. However, by using this window, we required all individuals 
diagnosed with stage II and III to survive at least 8-months after their diagnosis. 
Given that one-year overall survival for elderly stage II and III CRC is relatively high, 
the extent of selection may not have a large impact on this analysis. We believe that 
the associated increase in validity outweighs the decrease in generalizability of the 
findings to individuals surviving less than 8 months after diagnosis.      
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Generalizability of results from SEER-Medicare 
All analyses were restricted by multiple criteria in order to ensure full 
healthcare utilization and treatment capture. Specifically, we required that all elderly 
individuals had at least 12 months pre- and 8-months post-diagnosis continuous 
enrollment in Medicare Parts A and B (and no HMO enrollment). Elderly individuals 
with HMO Medicare coverage may behave differently than those with Medicare fee-
for-service coverage only due to plan incentives and competition. For Specific Aim 2, 
we further restricted entry into the cohort based on linkage requirements for the two 
additional data sources. These criteria included having a claim for CRC surgery 
within 6-months from diagnosis at a hospital matched to the SEER-Medicare 
Hospital file, and a claim for a specific chemotherapeutic agent within 8-months of 
diagnosis that matched a UPIN from the AMA Physician Masterfile. Taken together, 
these exclusions may reduce the generalizability of our findings to the US elderly 
population.   
Influence of unmeasured factors in explaining oxaliplatin receipt 
Our models examining the influence of patient, physician, and hospital 
characteristics on the receipt of oxaliplatin explained close to 78% of the overall 
variation. However, unmeasured factors such as patient preferences for or against 
treatment, comorbidities not captured by the Charlson Comorbidity Index, or other 
physician preferences and hospital characteristics lacking in our data would likely 
increase explanatory power.        
 
E. FUTURE RESEARCH 
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Future research could build upon our findings and address some of the 
limitations mentioned above. First, further validation of capecitabine use should be 
undertaken in combination with the Medicare Part D data. It is likely that physician 
coding behavior for capecitabine will improve over time, as CMS continues to 
provide guidance on appropriate billing to providers and pharmacies. A longitudinal 
examination of the validity of capecitabine in Medicare claims (including Part D data) 
is indicated. Second, patterns of chemotherapy treatment among stage II and III 
CRC patients in private health insurance databases may shed light on the 
differences in patterns due to variation in insurance benefits and coverage. Third, 
the results from the multilevel analysis of factors associated with the receipt of 
oxaliplatin could be augmented or replicated in datasets with access to additional 
patient-level preference data. The Cancer Care Outcomes Research and 
Surveillance Consortium (CanCORs) collects information on patient reported 
outcomes and patient preferences and behaviors and may be an excellent resource 
for this analysis. 
 
F. CONCLUSIONS 
Validated Medicare definitions identified a substantial increase in oxaliplatin 
utilization from 2004-2007 for both on- and off-label indications. Patient 
characteristics were most influential in explaining the variation in oxaliplatin receipt 
among stage II/III CRC patients; however, future analysis should attempt to capture 
patient preferences. Off-label use of chemotherapeutic agents in stage II/III CRC 
was relatively common. In light of the RCT evidence, physicians should carefully 
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weigh the unknown/minimal benefits of treatment against potentially serious side 
effects when deciding whether to treat a patient off-label.
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APPENDIX A 
 
 Table 1A. Administrative codes used to identify receipt of any chemotherapy from Medicare 
claims 
  
Medicare claims field 
type Codes of interest 
ICD-9 diagnosis codes V58.1, V66.2, V67.2 
ICD-9 procedure codes 99.25 
HCPCS 964xx, 965xx, J9000-J9999 (include J8520 and J8521 for CRC), 
G0355-G0362, Q0083-Q0085 (for 2005 only) 
Revenue center codes 0331, 0332, and 0335 
Specific agent codes All HCPCS and NDCs listed for specific agents below 
  
Table 1B: Administrative codes used to identify receipt of any chemotherapy from Medicare 
claims 
   
Chemotherapeutic agent Cancer sitesa HCPCS codes (2000, 2002, 2005) 
5-FU CR, Breast, Ovary J9190 
Capecitabineb CR, Breast J8520, J8521 
Irinotecan CR, NSCL J9206 
Oxaliplatin CR C9205, J9263 
Bevacizumab CR, Breast, NSCL C9214, C9257, J9035, Q2024, S0116 
Cetuximab CR C9215, J9055 
Carboplatin Breast, Ovary, NSCL J9045 
Cisplatin Breast, Ovary, NSCL C9418, J9060, J9062 
Cyclophosphamidec Breast, Ovary, NSCL C9420, C9421, C9421, J8530, J9070 - J9097 
Doxorubicin Breast, Ovary, NSCL C9415, J9000, J9001, J9010 
Epirubicin Breast C1167, J9178, J9180 
Trastuzumab Breast J9355 
Methotrexate Breast, NSCL J8610, J9250, J9260 
Paclitaxel  Breast, Ovary, NSCL C9431, C9127, J9264, J9265, S1016 
Docetaxel Breast, NSCL J9170, J9171 
Etoposide Ovary, NSCL C9414, C9425, J8560, J9181, J9182 
Ifosfamide Ovary C9427, J9208 
Gemcitabine Breast, NSCL J9201 
Alimta/Pemetrexed NSCL C9213, J9305 
Iressa/Gefitnib NSCL J8565 
Mitomycin C  NSCL C9432, J9280, J9290, J9291  
Vinblastine NSCL J9360 
Vincristine NSCL J9370, J9375, J9380 
Vinorelbine NSCL C9440, J9390 
a CR= Colorectal, NSCL = Non-small cell lung 
b To identify oral capecitabine in the DME files, we used the following National Drug Codes (NDCs): 
00004110020, 00004110150, 00004110116, 00004110051, 00004110013, 00004110022, 
00004110113, and 00004110151. 
c To identify oral cyclophosphamide in the DME files, we used the following NDCs: 00015-0503-01, 
00015-0503-02, 00015-0504-01, 00054-4129-25, 00054-4130-25, 00054-8089-25, 00054-8130-25.  
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APPENDIX B 
 
Table 1. Sample size reductions for exclusion criteria, 6-month cohort by cancer site and diagnosis year 
Cancer site 
Dx 
year Reason for exclusion 
N 
excluded 
% 
excluded 
N 
Remaining 
Breast 2005 Initial POC cohort 0 - 316 
Lacking verified treatment information 48 15.2 268 
Enrolled in a trial 20 6.3 248 
Lacking A+ B for 6-mo post-dx 21 6.6 227 
HMO coverage during 6-mo post-dx 69 21.8 158 
Subsequent cancer dx in <12 mo 1 0.3 157 
No claims in the 6-mo post-dx 2 0.6 155 
% of initial cohort remaining for analysis 49.1 
Breast 2000 Initial POC cohort 0 - 376 
Lacking verified treatment information 131 34.8 245 
Enrolled in a trial 6 1.6 239 
Lacking A+ B for 6-mo post-dx 18 4.8 221 
HMO coverage during 6-mo post-dx 60 16.0 161 
Subsequent cancer dx in <12 mo 3 0.8 158 
No claims in the 6-mo post-dx 2 0.5 156 
% of initial cohort remaining for analysis 41.5 
 Colorectal 2000 Initial POC cohort 0 - 476 
Lacking verified treatment information 156 32.8 320 
Enrolled in a trial for 6-mo post-dx 7 1.5 313 
Lacking A+ B 49 10.3 264 
HMO coverage during 6-mo post-dx 89 18.7 175 
Subsequent cancer dx in <12 mo 2 0.4 173 
No claims in the 6-mo post-dx 2 0.4 171 
% of initial cohort remaining for analysis 35.9 
 Colorectal 2005 Initial POC cohort 0 - 767 
Lacking verified treatment information 172 22.4 595 
Enrolled in a trial 36 4.7 559 
Lacking A+ B for 6-mo post-dx 97 12.6 462 
HMO coverage during 6-mo post-dx 118 15.4 344 
Subsequent cancer dx in <12 mo 5 0.7 339 
No claims in the 6-mo post-dx 1 0.1 338 
% of initial cohort remaining for analysis 44.1 
   129 
Non-Small Cell Lung 2005 Initial POC cohort 0 - 627 
Lacking verified treatment information 144 23.0 483 
Enrolled in a trial 28 4.5 455 
Lacking A+ B for 6-mo post-dx 165 26.3 290 
HMO coverage during 6-mo post-dx 77 12.3 213 
Subsequent cancer dx in <12 mo 3 0.5 210 
No claims in the 6-mo post-dx 15 2.4 195 
% of initial cohort remaining for analysis 31.1 
Ovary 2002 Initial POC cohort 0 - 446 
Lacking verified treatment information 122 27.4 324 
Enrolled in a trial 17 3.8 307 
Lacking A+ B for 6-mo post-dx 85 19.1 222 
HMO coverage during 6-mo post-dx 41 9.2 181 
Subsequent cancer dx in <12 mo 4 0.9 177 
No claims in the 6-mo post-dx 7 1.6 170 
% of initial cohort remaining for analysis 38.1 
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APPENDIX C 
 
Table 1. Comparison of specific chemotherapeutic agents identified by SEER POC data and Medicare claims during the 8-month post-
diagnosis period using a 61 day window after first chemo claim to define receipt of specific agents* 
Source reporting receipt of specific agent  
 
Specific agents 
POC=Yes, 
Med=Yes 
POC=No, 
Med=No 
POC=Yes, 
Med=No 
POC=No, 
Med=Yes 
Kappa 
(%) 
(95% CI) 
Se (%) 
(95% CI) 
Sp (%)  
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
     5-Fluorouracil 114 182 10 13 85 (79, 91) 92 (86, 96) 93 (89, 96) 90 (83, 94) 95 (91, 97) 
Capecitabine 21 270 23 5 55 (40, 71) 48 (32, 63) 98 (96, 99) 81 (61, 93) 92 (88, 95) 
Oxaliplatin 56 244 8 11 82 (74, 90) 88 (77, 94) 96 (92, 98) 84 (73, 92) 97 (94, 99) 
POC = Patterns of Care, Med=Medicare, Se = Sensitivity, Sp = Specificity, PPV = Positive predictive value, NPV = Negative predictive value 
* Individuals lacking treatment data for the specific agent of interest and those with POC administration dates >244 days from diagnosis were 
excluded from analysis. 
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